<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="pmc-domain-id">3416</journal-id><journal-id journal-id-type="pmc-domain">molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429930</article-id><article-id pub-id-type="pmcid-ver">PMC12429930.1</article-id><article-id pub-id-type="pmcaid">12429930</article-id><article-id pub-id-type="pmcaiid">12429930</article-id><article-id pub-id-type="doi">10.3390/molecules30173628</article-id><article-id pub-id-type="publisher-id">molecules-30-03628</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Microbiota-Derived Tryptophan Metabolite Indole-3-Propionic Acid-Emerging Role in Neuroprotection</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-1116-7327</contrib-id><name name-style="western"><surname>Owe-Larsson</surname><given-names initials="M">Maja</given-names></name><xref rid="af1-molecules-30-03628" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6072-2513</contrib-id><name name-style="western"><surname>Drobek</surname><given-names initials="D">Dominik</given-names></name><xref rid="af2-molecules-30-03628" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6351-9772</contrib-id><name name-style="western"><surname>Iwaniak</surname><given-names initials="P">Paulina</given-names></name><xref rid="af2-molecules-30-03628" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kloc</surname><given-names initials="R">Renata</given-names></name><xref rid="af2-molecules-30-03628" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2704-528X</contrib-id><name name-style="western"><surname>Urbanska</surname><given-names initials="EM">Ewa M.</given-names></name><xref rid="af2-molecules-30-03628" ref-type="aff">2</xref><xref rid="c1-molecules-30-03628" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5912-5324</contrib-id><name name-style="western"><surname>Chwil</surname><given-names initials="M">Miros&#322;awa</given-names></name><xref rid="af3-molecules-30-03628" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Sabatier</surname><given-names initials="JM">Jean-Marc</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-30-03628"><label>1</label>Department of Histology and Embryology, Center of Biostructure Research, Medical University of Warsaw, Cha&#322;ubi&#324;skiego 5, 02-004 Warsaw, Poland; <email>maja.owe-larsson@wum.edu.pl</email></aff><aff id="af2-molecules-30-03628"><label>2</label>Chair and Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland; <email>ddrobek0@icloud.com</email> (D.D.); <email>paulina.iwaniak@umlub.edu.pl</email> (P.I.); <email>renata.kloc@umlub.edu.pl</email> (R.K.)</aff><aff id="af3-molecules-30-03628"><label>3</label>Department of Botany and Plant Physiology, University of Life Sciences in Lublin, Akademicka 15, 20-950 Lublin, Poland; <email>miroslawa.chwil@up.lublin.pl</email></aff><author-notes><corresp id="c1-molecules-30-03628"><label>*</label>Correspondence: <email>ewa.urbanska@umlub.edu.pl</email></corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>30</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496502</issue-id><elocation-id>3628</elocation-id><history><date date-type="received"><day>17</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>01</day><month>9</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>05</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="molecules-30-03628.pdf"/><abstract><p>In recent years, gut&#8211;brain axis signaling has been recognized as an essential factor modifying behavior, mood, cognition, and cellular viability under physiological and pathological conditions. Consequently, the intestinal microbiome has become a potential therapeutic target in neurological and psychiatric disorders. The microbiota-derived metabolite of tryptophan (Trp), indole-3-propionic acid (IPA), was discovered to target a number of molecular processes and to impact brain function. In this review, we outline the key mechanisms by which IPA may affect neuronal activity and survival and provide an update on the evidence supporting the neuroprotective action of the compound in various experimental paradigms. Accumulating data indicates that IPA is a free radical scavenger, a ligand of aryl hydrocarbon receptors (AhR) and pregnane X receptors (PXR), and an anti-inflammatory molecule. IPA decreases the synthesis of the proinflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B), tumor necrosis factor-&#945; (TNF-&#945;), and other cytokines, reduces the generation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, and enhances the synthesis of neurotrophic factors. Furthermore, produced in the gut, or administered orally, IPA boosts the central levels of kynurenic acid (KYNA), a neuroprotective metabolite of Trp. IPA reduces the release of proinflammatory molecules in the gut, breaking the gut&#8211;inflammation&#8211;brain vicious cycle, which otherwise leads to neuronal loss. Moreover, as a molecule that easily enters central compartment, IPA may directly impact brain function and cellular survival. Overall, the gathered data confirms neuroprotective features of IPA, and supports its potential use in high-risk populations, in order to delay the onset and ameliorate the course of neurodegenerative disorders and cognitive impairment. Clinical trials evaluating IPA as a promising therapeutic add-on, able to slow down the progress of neurodegenerative disorders such as Alzheimer&#8217;s or Parkinson&#8217;s disease and to limit the morphological and behavioral consequences of ischemic stroke, are urgently needed.</p></abstract><kwd-group><kwd>indole-3-propionic acid</kwd><kwd>neuronal loss</kwd><kwd>microbiota</kwd><kwd>tryptophan</kwd><kwd>kynurenic acid</kwd><kwd>Alzheimer&#8217;s disease</kwd><kwd>Parkinson&#8217;s disease</kwd><kwd>stroke</kwd><kwd>inflammation</kwd><kwd>aryl hydrocarbon receptor</kwd><kwd>pregnane X receptor</kwd></kwd-group><funding-group><award-group><funding-source>University of Life Sciences in Lublin</funding-source></award-group><funding-statement>This research received no external funding. The APC was funded by University of Life Sciences in Lublin.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-molecules-30-03628"><title>1. Introduction</title><p>The importance of the gut&#8211;brain axis in the functioning of the central nervous system is well-recognized and broadly accepted. Intriguing discoveries of the last decades implicate the intestinal microbiome as a potential therapeutic target in neurological and psychiatric disorders [<xref rid="B1-molecules-30-03628" ref-type="bibr">1</xref>,<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>,<xref rid="B3-molecules-30-03628" ref-type="bibr">3</xref>,<xref rid="B4-molecules-30-03628" ref-type="bibr">4</xref>]. In the gut, tryptophan (Trp), an essential amino acid obtained from dietary sources, undergoes metabolic conversion by host and microbiota cells. Intestinal metabolism of Trp involves three major pathways (<xref rid="molecules-30-03628-f001" ref-type="fig">Figure 1</xref>). Trp is a substrate for the production of (A) serotonin by enterochromaffin cells and microbiota, (B) so-called kynurenines along the kynurenine pathway (KP) by immunocompetent and epithelial cells, and (C) various bioactive compounds, mostly indoles, by microbiota [<xref rid="B5-molecules-30-03628" ref-type="bibr">5</xref>,<xref rid="B6-molecules-30-03628" ref-type="bibr">6</xref>]. It is estimated that 4&#8211;6% of dietary Trp is metabolized along the indole pyruvate pathway [<xref rid="B6-molecules-30-03628" ref-type="bibr">6</xref>]. The most abundant metabolite is indole, followed by indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) [<xref rid="B7-molecules-30-03628" ref-type="bibr">7</xref>,<xref rid="B8-molecules-30-03628" ref-type="bibr">8</xref>,<xref rid="B9-molecules-30-03628" ref-type="bibr">9</xref>]. Emerging data demonstrate that indoles exert a profound impact on metabolic, immune, cardiovascular, and brain function [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>]. Microbiota-derived IPA possesses strong antioxidant and neuroprotective properties, and may ameliorate metabolic, inflammatory, and neurodegenerative changes in various experimental paradigms [<xref rid="B1-molecules-30-03628" ref-type="bibr">1</xref>,<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>,<xref rid="B3-molecules-30-03628" ref-type="bibr">3</xref>,<xref rid="B4-molecules-30-03628" ref-type="bibr">4</xref>].</p><p>This narrative review aims to present the current state of knowledge on IPA targets and discuss their potential benefits and drawbacks in the treatment of neurodegeneration.</p></sec><sec id="sec2-molecules-30-03628"><title>2. IPA Synthesis and Tissue Levels</title><p>IPA is primarily of bacterial origin. It is synthesized by species populating the soil and by intestinal microbiota residing in the human gut. IPA-producing bacteria originate from the <italic toggle="yes">Clostridiaceae</italic> and <italic toggle="yes">Peptostreptococcaceae</italic> families [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>]. Microbial phyla firmicutes (<italic toggle="yes">Roseburia</italic>, <italic toggle="yes">Dorea</italic>, <italic toggle="yes">Butyricicoccus</italic>, <italic toggle="yes">Ruminococcus</italic>, <italic toggle="yes">Eubacterium</italic>, <italic toggle="yes">Faecalibacterium</italic>, <italic toggle="yes">Gemmiger</italic>, <italic toggle="yes">Intestinimonas</italic>, <italic toggle="yes">Sporobacter</italic>, <italic toggle="yes">Oscillibacter</italic>, <italic toggle="yes">Clostridium_XlVb</italic>, and <italic toggle="yes">Coprococcus</italic>), actinobacteria (<italic toggle="yes">Adlercreutzia</italic>, <italic toggle="yes">Collinsella</italic>), bacteroidetes (<italic toggle="yes">Prevotella</italic>, <italic toggle="yes">Alistipes</italic>, <italic toggle="yes">Odoribacter</italic>), and verrucomicrobia (<italic toggle="yes">Akkermansia</italic>) were positively linked with serum IPA levels in a cohort of 318 adults [<xref rid="B11-molecules-30-03628" ref-type="bibr">11</xref>]. The mechanisms underlying the metabolism of Trp to IPA are analogous to the processes by which <italic toggle="yes">C. sporogenes</italic> converts phenylalanine into phenylpropionic acid. The specific fldC gene associated with IPA production was identified, and the knockout of the fldC gene completely abolished the generation of IPA [<xref rid="B12-molecules-30-03628" ref-type="bibr">12</xref>].</p><p>IPA synthesis depends predominantly on the activity of Trp aminotransferase (TAA/ArAT, aromatic amino acid aminotransferase) [<xref rid="B13-molecules-30-03628" ref-type="bibr">13</xref>]. ArAT converts Trp to indole-3-pyruvic acid (IPyA), which is later reduced to indolelactic acid (ILA) by indolelactate dehydrogenase (ILDH). ILA is dehydrated to indoleacrylic acid (IA) by phenyllactate dehydratase BC (fldBC) and its activator, acyl-CoA ligase. The final product of Trp reductive metabolism, IPA, is produced from IA by acyl-CoA dehydrogenase (acdA) [<xref rid="B9-molecules-30-03628" ref-type="bibr">9</xref>,<xref rid="B12-molecules-30-03628" ref-type="bibr">12</xref>] (<xref rid="molecules-30-03628-f001" ref-type="fig">Figure 1</xref>).</p><p>The circulating levels of IPA depend on the diversity of intestinal microbiota, the level of Trp supply, the type of ingested food, and the relative activity of other metabolic pathways that convert Trp. IPA can also be found in some food products, such as various plant species of the family Brassicaceae or female asparagus plants (<italic toggle="yes">Asparagus officinalis</italic> L.) [<xref rid="B12-molecules-30-03628" ref-type="bibr">12</xref>,<xref rid="B14-molecules-30-03628" ref-type="bibr">14</xref>,<xref rid="B15-molecules-30-03628" ref-type="bibr">15</xref>].</p><p>The impact of nutritional factors on the intestinal milieu, bacterial diversity, and, subsequently, IPA synthesis was shown by several studies. In a large cohort of individuals (N = 1018), the microbiome alpha-diversity was linked with serum IPA levels [<xref rid="B16-molecules-30-03628" ref-type="bibr">16</xref>]. In line with this observation, in women with low IPA levels and polycystic ovary syndrome, the alpha-diversity of microbiota and dietary intake of whole-grain cereals were lower [<xref rid="B17-molecules-30-03628" ref-type="bibr">17</xref>]. The impact of diet was demonstrated in healthy volunteers fed a high-fat, low-fiber diet for a short period. This resulted in an altered ratio of intestinal microbiota species and a subsequent decrease in IPA synthesis [<xref rid="B18-molecules-30-03628" ref-type="bibr">18</xref>]. In another study, fiber and carbohydrate intake were correlated with circulating levels of IPA in healthy controls and individuals predisposed to diabetes [<xref rid="B19-molecules-30-03628" ref-type="bibr">19</xref>]. Consequently, prolonged administration of probiotic strains of <italic toggle="yes">Bifidobacterium</italic> in a randomized, double-blind clinical trial (N = 31) resulted in an almost two-fold increase in serum IPA level. Furthermore, a Trp-rich diet potently increases peripheral levels of IPA [<xref rid="B20-molecules-30-03628" ref-type="bibr">20</xref>,<xref rid="B21-molecules-30-03628" ref-type="bibr">21</xref>].</p><p>IPA, generated by microbiota, enters epithelial cells, where it can reach its first targets in the gut&#8211;brain axis, such as the aryl hydrocarbon receptor (AhR) and pregnane X receptor (PXR), which are primarily involved in immune response modulation. Upon absorption from the GI, IPA is distributed systemically, and, in the process of simple diffusion, easily crosses the blood&#8211;brain barrier. It was discovered that brain IPA is not produced in situ, but derives from systemic circulation, and microbial metabolism of Trp to indole derivatives is indispensable in this process [<xref rid="B14-molecules-30-03628" ref-type="bibr">14</xref>,<xref rid="B22-molecules-30-03628" ref-type="bibr">22</xref>,<xref rid="B23-molecules-30-03628" ref-type="bibr">23</xref>].</p><p>The levels of IPA in body fluids vary between species. In rats, IPA concentration reached approximately 5 &#956;M in the blood [<xref rid="B24-molecules-30-03628" ref-type="bibr">24</xref>]. In humans, serum IPA levels are approximately 100&#8211;200 ng/mL, i.e., a 0.5&#8211;1 &#956;M concentration [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B23-molecules-30-03628" ref-type="bibr">23</xref>]. Clinical data from various cohorts revealed control serum levels of IPA from 107 to 190 ng/mL (0.5&#8211;1.3 &#956;M), and its decrease in Huntington&#8217;s disease (HD) or Parkinson&#8217;s disease (PD) by 40&#8211;50% [<xref rid="B25-molecules-30-03628" ref-type="bibr">25</xref>,<xref rid="B26-molecules-30-03628" ref-type="bibr">26</xref>,<xref rid="B27-molecules-30-03628" ref-type="bibr">27</xref>].</p><p>Studies on the cerebrospinal fluid (CSF) level of IPA are scarce. Human CSF IPA is much lower than in serum and was estimated at 0.63 &#177; 0.09 ng/mL, i.e., approximately 3 nM [<xref rid="B14-molecules-30-03628" ref-type="bibr">14</xref>]. In rats, IPA levels reach 20 ng/mL (approximately 0.1 &#956;M) [<xref rid="B28-molecules-30-03628" ref-type="bibr">28</xref>]. In the brain, IPA levels are slightly lower; however, peripheral administration of this compound evokes a 2&#8211;3-fold rise, as shown in experimental animals [<xref rid="B14-molecules-30-03628" ref-type="bibr">14</xref>,<xref rid="B28-molecules-30-03628" ref-type="bibr">28</xref>,<xref rid="B29-molecules-30-03628" ref-type="bibr">29</xref>,<xref rid="B30-molecules-30-03628" ref-type="bibr">30</xref>].</p><p>Consequently, diet composition should be taken into consideration when planning studies and analyzing the impact of gut-derived IPA on brain function.</p></sec><sec id="sec3-molecules-30-03628"><title>3. Targets of IPA</title><p>IPA modulates human metabolism, immune response, and cardiovascular and brain function through various molecular targets. Accumulating data have shown that IPA acts as a free radical scavenger, a ligand of aryl hydrocarbon receptors (AhR) and pregnane X receptors (PXR). It improves the integrity of the intestinal barrier and alleviates inflammation [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B31-molecules-30-03628" ref-type="bibr">31</xref>,<xref rid="B32-molecules-30-03628" ref-type="bibr">32</xref>]. A correlation between serum IPA and brain-derived neurotrophic factor (BDNF) was demonstrated [<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>]. Furthermore, orally administered IPA may increase the level of kynurenic acid (KYNA), a neuroprotective metabolite of Trp [<xref rid="B34-molecules-30-03628" ref-type="bibr">34</xref>] (<xref rid="molecules-30-03628-f002" ref-type="fig">Figure 2</xref>, <xref rid="molecules-30-03628-t001" ref-type="table">Table 1</xref>, <xref rid="molecules-30-03628-t002" ref-type="table">Table 2</xref>).</p><sec id="sec3dot1-molecules-30-03628"><title>3.1. Aryl Hydrocarbon Receptor</title><p>Aryl hydrocarbon receptor (AhR) is an 848-amino-acid transcription factor encoded by the <italic toggle="yes">AHR</italic> gene on chromosome 7p21.1 in humans [<xref rid="B61-molecules-30-03628" ref-type="bibr">61</xref>,<xref rid="B62-molecules-30-03628" ref-type="bibr">62</xref>,<xref rid="B63-molecules-30-03628" ref-type="bibr">63</xref>,<xref rid="B64-molecules-30-03628" ref-type="bibr">64</xref>]. Inactive cytoplasmic AhR forms a complex with cochaperone p23, a heat-shock protein, an AhR-interacting protein, and an SRC protein kinase. Upon binding an AhR ligand, the complex undergoes conformational changes, translocates to the nucleus, and there controls the transcription of a variety of genes [<xref rid="B62-molecules-30-03628" ref-type="bibr">62</xref>]. The major role of AhR was initially ascribed to xenobiotic detoxification and protection against environmental toxins. Currently, it is broadly accepted that the role of AhR in human physiology is quite complex. The net outcome of its activation depends on the cell type, ontogenetic period of life, and the presence or absence of other signaling molecules/pathogenetic factors [<xref rid="B65-molecules-30-03628" ref-type="bibr">65</xref>,<xref rid="B66-molecules-30-03628" ref-type="bibr">66</xref>].</p><p>Apart from regulating transcription, AhR may target the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B), estrogen, or retinoic acid receptors [<xref rid="B63-molecules-30-03628" ref-type="bibr">63</xref>,<xref rid="B67-molecules-30-03628" ref-type="bibr">67</xref>,<xref rid="B68-molecules-30-03628" ref-type="bibr">68</xref>]. AhR may also act as a ubiquitin ligase, which impacts the processes of ubiquitination and proteasomal degradation, and contributes to the regulation of cell division [<xref rid="B69-molecules-30-03628" ref-type="bibr">69</xref>]. AhR changes histone acetylation and methylation and influences the long non-coding RNA and microRNAs [<xref rid="B63-molecules-30-03628" ref-type="bibr">63</xref>,<xref rid="B68-molecules-30-03628" ref-type="bibr">68</xref>]. Furthermore, activation of AhR may impact the metabolism of Trp along the kynurenine pathway. The protein kinase SCR, released upon ligand binding to AhR, phosphorylates the indoleamine 2,3-dioxygenase 1 (IDO1), and, thus, affects the fate of Trp metabolism [<xref rid="B70-molecules-30-03628" ref-type="bibr">70</xref>].</p><p>In peripheral organs, AhR is expressed in vascular cells and impacts the endothelial barriers, including the gut&#8211;brain axis [<xref rid="B67-molecules-30-03628" ref-type="bibr">67</xref>,<xref rid="B68-molecules-30-03628" ref-type="bibr">68</xref>]. It is considered essential for the balance between the development of antigen tolerance, on one side, and the immune defense against pathogenic microbial species on the other [<xref rid="B68-molecules-30-03628" ref-type="bibr">68</xref>]. In the brain, apart from vascular cells, AhR is extensively expressed in neurons, astrocytes, and microglia [<xref rid="B55-molecules-30-03628" ref-type="bibr">55</xref>,<xref rid="B58-molecules-30-03628" ref-type="bibr">58</xref>]. The expression of AhR depends on the stage of development and is region- and cell-dependent [<xref rid="B71-molecules-30-03628" ref-type="bibr">71</xref>].</p><p>The gut&#8211;brain axis, which involves interactions of intestinal ligands with peripheral and central AhR receptors, is considered an important element of proper brain function [<xref rid="B63-molecules-30-03628" ref-type="bibr">63</xref>,<xref rid="B68-molecules-30-03628" ref-type="bibr">68</xref>]. Microbiota-produced indoles, as well as many kynurenines, are recognized as potent AhR ligands [<xref rid="B72-molecules-30-03628" ref-type="bibr">72</xref>]. However, despite several publications referring to IPA as an AhR ligand, the available data are ambiguous.</p><p>Studies that support IPA as an AhR agonist employed various experimental approaches. First, the effects of IPA were reversed in vivo by an AhR antagonist, as demonstrated, e.g., in a murine sepsis model [<xref rid="B73-molecules-30-03628" ref-type="bibr">73</xref>]. Secondly, the level of AhR protein following exposure to certain indoles was increased, as shown in beta-amyloid (A&#946;) precursor protein (APP)/PS1 mice in which a mixture of indoles, including IPA, upregulated the brain expression of AhR protein [<xref rid="B43-molecules-30-03628" ref-type="bibr">43</xref>]. However, this effect was not specific to IPA, and the authors did not assess the affinity of the studied indoles to AhR. More precise conclusions were drawn in the study on an osteoarthritis model, where AhR knockdown abolished the IPA-evoked anti-inflammatory effects [<xref rid="B74-molecules-30-03628" ref-type="bibr">74</xref>]. Other authors were unable to confirm the activation of AhR by IPA, as shown in 293T cells [<xref rid="B75-molecules-30-03628" ref-type="bibr">75</xref>].</p><p>The net effect of IPA may depend on the presence of other ligands in the milieu. IPA blocked the effect of another AhR agonist, indoxyl sulfate, which is considered a uremic toxin. In cultured proximal tubular cells, IPA diminished the augmented expression of AHR, cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1), transforming growth factor &#946;1 (TGF-&#946;1), and monocyte chemoattractant protein-1 (MCP-1), possibly through the signal transducer and activator of transcription 3 (STAT3) suppression [<xref rid="B76-molecules-30-03628" ref-type="bibr">76</xref>]. In at least two other studies, in an environment with different indoles present, the action of IPA on AhR was suggested to be unpredictable and varying [<xref rid="B77-molecules-30-03628" ref-type="bibr">77</xref>,<xref rid="B78-molecules-30-03628" ref-type="bibr">78</xref>]. Thus, considering the data gathered so far, the AhR receptor mediates the action of IPA. However, the degree of the effect is not fully predictable, since AHR signaling depends on other transcription factors, the proportion of various ligands in the extracellular milieu, and the cell type expressing the receptor.</p><p>The impact of IPA on the brain seems to be mediated by at least two pathways. First, intestinal IPA may alleviate local inflammation, and reduce the release of proinflammatory molecules, thus breaking the vicious cycle culminating in brain disorders. A rapidly growing amount of data supports the concept of the gut&#8211;brain axis viewed as the interaction of intestinal microbiota- and host cells-produced metabolites with the central nervous system. Special emphasis concerns the detrimental role of even subtle, yet chronic, inflammation. In such a scenario, a deficit of anti-inflammatory compounds may initiate processes culminating in morphological alteration and dysfunction of the brain. Secondly, when circulating IPA reaches the central compartment, it can directly modulate cellular processes through genomic, epigenetic, and receptor-linked switches.</p></sec><sec id="sec3dot2-molecules-30-03628"><title>3.2. Pregnane X Receptor</title><p>The pregnane X receptor (PXR) is encoded by the <italic toggle="yes">nuclear receptor subfamily 1 group I member 2</italic> (<italic toggle="yes">NR1I2</italic>) gene on chromosome 3q13.33 [<xref rid="B79-molecules-30-03628" ref-type="bibr">79</xref>]. PXR is expressed within the cells of the enterohepatic system, immunocompetent cells such as lymphocytes, monocytes, or macrophages [<xref rid="B80-molecules-30-03628" ref-type="bibr">80</xref>]. However, other cells and organs, including neurons and blood&#8211;brain-barrier endothelium, express PXR [<xref rid="B81-molecules-30-03628" ref-type="bibr">81</xref>]. The primary action of PXR, similarly to AhR, relates to modulation of xenobiotics and drug metabolism and transport, e.g., through changes in the hepatic cytochrome P450, family 3, subfamily A (CYP3A) enzyme or the organic anion-transporting polypeptide 1a4 (Oatp1a4). Subsequently, drugs and xenobiotics are cleared from the body [<xref rid="B82-molecules-30-03628" ref-type="bibr">82</xref>,<xref rid="B83-molecules-30-03628" ref-type="bibr">83</xref>,<xref rid="B84-molecules-30-03628" ref-type="bibr">84</xref>]. Again, similarly to AhR, PXR may exert non-genomic effects, including, e.g., interactions with NFkB, Toll-like receptors (TLRs), or the inflammasome. It also impacts cellular energetics and apoptotic processes [<xref rid="B85-molecules-30-03628" ref-type="bibr">85</xref>,<xref rid="B86-molecules-30-03628" ref-type="bibr">86</xref>].</p><p>An important aspect of brain PXR activation is associated with the metabolism of neurosteroids, which, in turn, may affect behavior and neuronal survival [<xref rid="B87-molecules-30-03628" ref-type="bibr">87</xref>]. It is assumed that the neurotoxic effect of various xenobiotics may be in part mediated by PXR, which changes the expression of mitochondrial CYP450 and alters mitochondrial function [<xref rid="B81-molecules-30-03628" ref-type="bibr">81</xref>]. Interestingly, there are significant inter-species differences in ligand affinity or selectivity in the case of PXR, similar to those in the case of AhR [<xref rid="B86-molecules-30-03628" ref-type="bibr">86</xref>]. Moreover, the effects of PXR activation vary between species and cell types, and depend on the used ligand [<xref rid="B81-molecules-30-03628" ref-type="bibr">81</xref>].</p><p>IPA seems to be a rather weak agonist for human PXR, with a half maximal effective concentration (EC<sub>50</sub>) of 120 &#956;M. However, when co-administered with indole, IPA activates PXR in a much stronger manner. Mouse PXR is stimulated by IPA with much higher specificity (EC<sub>50</sub> of 0.55 &#956;M) [<xref rid="B75-molecules-30-03628" ref-type="bibr">75</xref>]. In mouse models of PD, administration of IPA decreased the permeability of the intestinal barrier and blood&#8211;brain barrier (BBB), ameliorated inflammation, and improved dopaminergic neuronal function in a PXR-dependent manner, with a possible involvement of the Janus kinase 1 (JAK1)/STAT6 pathway [<xref rid="B37-molecules-30-03628" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot3-molecules-30-03628"><title>3.3. Free Radical Scavenging</title><p>IPA is a hydroxyl radical scavenger acting over two-fold more potent than melatonin, a structurally and biochemically similar Trp derivative. The compound acts as an endogenous electron donor, scavenging free radicals effectively and preventing oxidative damage without undergoing autoxidation during the redox recycling of transition metals. It detoxifies highly reactive free radicals by donating electrons to hydroxyl anions [<xref rid="B88-molecules-30-03628" ref-type="bibr">88</xref>,<xref rid="B89-molecules-30-03628" ref-type="bibr">89</xref>,<xref rid="B90-molecules-30-03628" ref-type="bibr">90</xref>].</p><p>IPA penetrates mitochondria, binds to complex I of the respiratory chain, and stabilizes energy metabolism, thereby lowering reactive oxygen species production [<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>]. Additionally, IPA has been observed to work in synergy with glutathione, another antioxidant, to inhibit the formation of cationic free radicals, further enhancing its protective effects [<xref rid="B28-molecules-30-03628" ref-type="bibr">28</xref>]. IPA and its derivative, indolepropionamide (IPAM), reduced hydroxyl radical generation and inhibited the age-dependent impairment of mitochondrial function [<xref rid="B91-molecules-30-03628" ref-type="bibr">91</xref>]. Furthermore, IPA protects DNA from oxidative injury, as shown in various models of DNA damage [<xref rid="B92-molecules-30-03628" ref-type="bibr">92</xref>,<xref rid="B93-molecules-30-03628" ref-type="bibr">93</xref>]. The action of IPA results from the prevention of lipid peroxidation and inhibition of the synthesis of proinflammatory cytokines [<xref rid="B35-molecules-30-03628" ref-type="bibr">35</xref>,<xref rid="B94-molecules-30-03628" ref-type="bibr">94</xref>,<xref rid="B95-molecules-30-03628" ref-type="bibr">95</xref>]. Antioxidant effects of IPA are also evident in vivo. In Mongolian gerbils subjected to transient forebrain ischemia, orally administered IPA decreased lipid peroxidation in the hippocampus and reduced DNA damage in pyramidal neurons of the CA1 area [<xref rid="B30-molecules-30-03628" ref-type="bibr">30</xref>].</p></sec><sec id="sec3dot4-molecules-30-03628"><title>3.4. Anti-Inflammatory Properties</title><p>Compelling data indicate that IPA acts as a potent anti-inflammatory molecule in various experimental paradigms [<xref rid="B9-molecules-30-03628" ref-type="bibr">9</xref>,<xref rid="B96-molecules-30-03628" ref-type="bibr">96</xref>]. The beneficial effects of IPA were demonstrated in liver steatosis, metabolic disorders, insulin resistance, cardiovascular diseases, and bone diseases [<xref rid="B97-molecules-30-03628" ref-type="bibr">97</xref>,<xref rid="B98-molecules-30-03628" ref-type="bibr">98</xref>,<xref rid="B99-molecules-30-03628" ref-type="bibr">99</xref>].</p><p>The major mechanisms underlying the anti-inflammatory IPA effect comprise upregulated expression of AhR, decreased synthesis of the proinflammatory NF-&#954;B, tumor necrosis factor-&#945; (TNF-&#945;), and other cytokines, reduced generation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, or enhanced synthesis of neurotrophic factors [<xref rid="B41-molecules-30-03628" ref-type="bibr">41</xref>,<xref rid="B96-molecules-30-03628" ref-type="bibr">96</xref>]. IPA may also inhibit the AKT protein pathway, with subsequent higher expression of the anti-inflammatory interleukin 10 (IL-10) and a decline in inflammation [<xref rid="B100-molecules-30-03628" ref-type="bibr">100</xref>]. Recently, the ability of IPA to interfere with matrix metalloproteinase 9 (MMP9) was suggested [<xref rid="B101-molecules-30-03628" ref-type="bibr">101</xref>].</p><p>IPA suppressed IL-1&#946;-induced inflammation, extracellular matrix (ECM) degradation, and NF-&#954;B signaling activation in chondrocytes in an AhR-mediated way [<xref rid="B74-molecules-30-03628" ref-type="bibr">74</xref>]. AhR-dependent reduction in bacterial burden, protection against organ damage, and decreased sepsis-related mortality following IPA administration were shown [<xref rid="B73-molecules-30-03628" ref-type="bibr">73</xref>]. IPA regulated PPT1 expression to modulate the PI3K-AKT-mTOR pathway, thereby restoring autophagic activity in senescent macrophages and suppressing both inflammation and aging-related myocardial fibrosis. Additionally, IPA influenced the cGAS-STING signaling pathway to regulate PPT1 expression [<xref rid="B102-molecules-30-03628" ref-type="bibr">102</xref>].</p><p>Anti-inflammatory and neuroprotective effects of IPA are evident in the central nervous system. In primary human astrocytes, IPA attenuated the lipopolysaccharide (LPS)-evoked release of inflammatory cytokines, such as monocyte chemoattractant protein-1 (MCP-1), IL-12, IL-13, and TNF-&#945;, yet it did not change the level of KYN or the KYN/Trp ratio [<xref rid="B41-molecules-30-03628" ref-type="bibr">41</xref>]. A mixture of indole, indole-3-acetic acid, and IPA upregulated the expression of AhR, decreased the NF-&#954;B and generation of the NLRP3 inflammasome, and lowered the level of proinflammatory cytokines in APP/PS1 mice, a mouse model of Alzheimer&#8217;s disease (AD). Indoles also improved the integrity of the intestinal barrier, enhanced cognition, and ameliorated brain neuropathology in APP/PS1 mice [<xref rid="B43-molecules-30-03628" ref-type="bibr">43</xref>]. However, in the above study, the effect of IPA alone was not assessed.</p><p>Incubation of LPS-activated murine microglial BV2 cells in the presence of 1&#8211;5 &#956;M IPA for 6 h diminished the release of proinflammatory TNF-&#945; into incubation media. Furthermore, incubation with conditioned media from IPA-treated microglia restored BDNF and nerve growth factor (NGF) expression in neuroblastoma cells inhibited by LPS [<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>].</p><p>In mice, microdeletion of chromosomal region 16p11.2, known to contribute in humans to neurodevelopmental disorders, cognitive impairment, and dysbiosis, resulted in decreased IPA levels. In this model, orally administered IPA reversed hippocampal alterations and improved cognition, possibly as a result of an increased phosphorylation of ERK1 protein [<xref rid="B53-molecules-30-03628" ref-type="bibr">53</xref>].</p><p>A study in 32 healthy elderly individuals receiving probiotics for 12 weeks revealed a 1.91-fold increase in serum IPA. IPA level was linked with bacterial diversity and with serum BDNF level. In cultured murine microglial cells treated with 5 &#956;M IPA, the production of TNF-&#945; decreased. Moreover, in human neuroblastoma SH-SY5Y cells, application of media from IPA-treated microglia enhanced BDNF and nerve growth factor synthesis [<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>].</p></sec><sec id="sec3dot5-molecules-30-03628"><title>3.5. KYNA</title><p>More than 95% of dietary Trp is degraded along the kynurenine pathway (KP) into derivatives collectively called kynurenines [<xref rid="B103-molecules-30-03628" ref-type="bibr">103</xref>]. The metabolism of Trp starts with the conversion of N-formylkynurenine by two step-limiting enzymes, indoleamine 2,3-dioxygenase (IDO), and Trp 2,3-dioxygenase (TDO) [<xref rid="B104-molecules-30-03628" ref-type="bibr">104</xref>]. The expression of IDO is induced by inflammatory mediators, e.g., interferon gamma (IFN-&#947;), IL-6, or TNF-&#945; [<xref rid="B105-molecules-30-03628" ref-type="bibr">105</xref>]. A novel way of the Trp metabolism through an enzyme, IL-4-induced 1 (IL4I1), acting as an L-amino acid oxidase, was recently described [<xref rid="B106-molecules-30-03628" ref-type="bibr">106</xref>].</p><p>N-formylkynurenine is rapidly converted by formidase to the stable metabolite kynurenine, constituting the core of the pathway. Kynurenine is further metabolized along three major pathways. Firstly, it is transformed into KYNA by kynurenine aminotransferases (KATs) I-IV. Kynurenine can also be cleaved by kynureninase into anthranilic acid. Finally, kynurenine 3-monooxygenase (KMO) converts kynurenine to 3-hydroxykynurenine (3-HK). 3-HK is converted to xanthurenic acid or, through enzymatic and non-enzymatic conversion, with 3-hydroxyanthranilic acid as an intermediate, yields quinolinic acid (QUIN). The latter one is metabolized to nicotinamide adenine dinucleotide (NAD). Alternatively, 3-hydroxyanthranilic acid is converted to picolinic acid [<xref rid="B103-molecules-30-03628" ref-type="bibr">103</xref>,<xref rid="B107-molecules-30-03628" ref-type="bibr">107</xref>,<xref rid="B108-molecules-30-03628" ref-type="bibr">108</xref>].</p><p>Kynurenines manifest a plethora of biological effects in peripheral and central compartments, including modulation of immune response, cellular survival, and metabolism (for a detailed review see: [<xref rid="B109-molecules-30-03628" ref-type="bibr">109</xref>,<xref rid="B110-molecules-30-03628" ref-type="bibr">110</xref>,<xref rid="B111-molecules-30-03628" ref-type="bibr">111</xref>]). A broad array of data from various experimental paradigms revealed compromised function of the KP in cardiovascular, gastrointestinal, kidney tract, endocrine, or neuropsychiatric disorders, to name a few [<xref rid="B64-molecules-30-03628" ref-type="bibr">64</xref>,<xref rid="B112-molecules-30-03628" ref-type="bibr">112</xref>,<xref rid="B113-molecules-30-03628" ref-type="bibr">113</xref>]. These discoveries resulted in various pharmacological attempts aimed at manipulating the KP, which is considered a promising therapeutic target in human pathology. However, the interplay between various kynurenines, and their net impact on a given cell, and the organ dynamically changes. It depends primarily on the efficacy of biosynthetic and catabolic processes and the proportion between metabolites known to exert the opposing action [<xref rid="B114-molecules-30-03628" ref-type="bibr">114</xref>]. Interestingly, the oxidative status of the milieu seems increasingly important as it may alter the properties of metabolites from antioxidant to promoting oxidative stress [<xref rid="B109-molecules-30-03628" ref-type="bibr">109</xref>].</p><p>The classical neurotoxic metabolites of the KP include QUIN, an endogenous agonist of glutamatergic receptors of N-methyl-D-aspartate type (NMDA), and 3-HK, which generates free radicals. However, anthranilic acid, 3-hydroxyanthranilic acid, xanthurenic acid, picolinic acid, or kynurenine itself may all generate free radicals [<xref rid="B109-molecules-30-03628" ref-type="bibr">109</xref>,<xref rid="B115-molecules-30-03628" ref-type="bibr">115</xref>].</p><p>On the other hand, KYNA is a pleiotropic molecule, for years considered an endogenous antagonist of glutamate receptors with neuroprotective properties [<xref rid="B116-molecules-30-03628" ref-type="bibr">116</xref>]. With the years, the complex biological effects of KYNA have become unveiled [<xref rid="B105-molecules-30-03628" ref-type="bibr">105</xref>,<xref rid="B117-molecules-30-03628" ref-type="bibr">117</xref>]. Apart from the antagonism of iono- and metabotropic glutamate receptors, KYNA was reported to stimulate G-protein-coupled receptor 35 (GPR35), to act as a ligand of adrenoceptor alpha 2B (ADRA2B) and hydroxycarboxylic acid receptor 3 (HCAR3), and to stimulate the &#945;-7 nicotinic acetylcholine receptor (&#945;7nAChR), although the latter effect is a matter of debate [<xref rid="B64-molecules-30-03628" ref-type="bibr">64</xref>,<xref rid="B105-molecules-30-03628" ref-type="bibr">105</xref>,<xref rid="B110-molecules-30-03628" ref-type="bibr">110</xref>].</p><p>Furthermore, KYNA, similarly to other metabolites of the KP, such as kynurenine or xanthurenic acid, is an agonist of AhR, yet with higher potency than other kynurenines, showing an ED<sub>50</sub> of 100 nM-1 &#956;M [<xref rid="B105-molecules-30-03628" ref-type="bibr">105</xref>,<xref rid="B118-molecules-30-03628" ref-type="bibr">118</xref>,<xref rid="B119-molecules-30-03628" ref-type="bibr">119</xref>].</p><p>KYNA occurs in the serum, CSF, and various organs, including the brain. The concentration is within the 40&#8211;100 nM range. However, KYNA may attain much higher levels locally, for example, during inflammation [<xref rid="B105-molecules-30-03628" ref-type="bibr">105</xref>]. The classical KYNA synthesis pathway in the brain involves the conversion of L-kynurenine by KATs, and was initially ascribed to astroglial cells, but it is now believed that microglial and neuronal cells may also synthesize KYNA [<xref rid="B120-molecules-30-03628" ref-type="bibr">120</xref>]. It is noteworthy that peripheral KYNA practically does not reach the central compartment [<xref rid="B121-molecules-30-03628" ref-type="bibr">121</xref>].</p><p>Therefore, attempts to alter central KYNA level were aimed mostly to increase the brain concentration of KYNA substrate, kynurenine, or to use compounds that, upon penetration through the blood&#8211;brain barrier, may change the activity of KATs, or impede the conversion of kynurenine along the other two arms of the KP [<xref rid="B107-molecules-30-03628" ref-type="bibr">107</xref>,<xref rid="B122-molecules-30-03628" ref-type="bibr">122</xref>].</p><p>Recently, it was demonstrated that orally administered IPA may boost serum and brain KYNA, but not kynurenine levels in rodents [<xref rid="B34-molecules-30-03628" ref-type="bibr">34</xref>]. Moreover, sub-chronic treatment with IPA provided in the chow caused several-fold increases in both IPA and KYNA levels in the plasma and prefrontal cortex of the animals. In contrast, KYNA levels in medial prefrontal cortex and striatum were not affected by in situ IPA administration via microdialysis probe. Similarly, the addition of IPA to homogenates of rat prefrontal cortex tissue and recombinant human KATII did not influence KATII activity in concentrations up to 1 mM [<xref rid="B34-molecules-30-03628" ref-type="bibr">34</xref>]. Thus, IPA is a potent stimulator of KYNA production, acting most probably within the intestinal compartment. However, the precise mechanisms underlying this effect remain to be elucidated.</p></sec></sec><sec id="sec4-molecules-30-03628"><title>4. IPA and Neurodegeneration</title><p>Acute or chronically progressing neuronal loss is a hallmark of brain disorders such as stroke, trauma, neurodegenerative, or autoimmune diseases [<xref rid="B123-molecules-30-03628" ref-type="bibr">123</xref>,<xref rid="B124-molecules-30-03628" ref-type="bibr">124</xref>]. Underlying pathogenesis includes a network of processes triggered by exogenous, environmental, and genetically determined factors. An excessive release of glutamate enhanced intracellular Ca<sup>2+</sup> accumulation, and disturbed mitochondrial function, together with free radical generation, and abnormal buildup of misfolded proteins culminate in neuronal cell death [<xref rid="B3-molecules-30-03628" ref-type="bibr">3</xref>,<xref rid="B125-molecules-30-03628" ref-type="bibr">125</xref>,<xref rid="B126-molecules-30-03628" ref-type="bibr">126</xref>,<xref rid="B127-molecules-30-03628" ref-type="bibr">127</xref>]. Despite tremendous scientific efforts, currently approved drugs impact neurodegeneration in a limited way. The treatment is restricted to partial mitigation of the neuronal loss during acute brain events. In chronic neurodegeneration, therapies are symptomatic, able to ameliorate the manifestations of some disorders, but not to stop or reverse the course of the disease. There is an urgent need for the development of novel prophylactic and disease-modifying treatments.</p><p>The increasing understanding of the role played by intestinal microbiota and their metabolites in the function of the brain has resulted in the gut&#8211;brain hypothesis of neurodegeneration [<xref rid="B128-molecules-30-03628" ref-type="bibr">128</xref>,<xref rid="B129-molecules-30-03628" ref-type="bibr">129</xref>]. Accordingly, a number of interventions were proposed to improve the diversity of microbiota, to boost the population of beneficial species, and to use selected microbial metabolites as potential drugs [<xref rid="B129-molecules-30-03628" ref-type="bibr">129</xref>].</p><p>In view of the available data, IPA has emerged as a therapeutic molecule with promising neuroprotective potential. The compound, either produced by the microbiota or delivered orally, can easily cross the BBB and impact neuronal function through several processes described above, with subsequent changes in neurotransmission, impairment of inflammation, and protection against free radical-induced damage [<xref rid="B35-molecules-30-03628" ref-type="bibr">35</xref>,<xref rid="B94-molecules-30-03628" ref-type="bibr">94</xref>,<xref rid="B95-molecules-30-03628" ref-type="bibr">95</xref>]. Peripherally administered IPA easily reaches the brain and may attain high levels [<xref rid="B14-molecules-30-03628" ref-type="bibr">14</xref>,<xref rid="B28-molecules-30-03628" ref-type="bibr">28</xref>,<xref rid="B29-molecules-30-03628" ref-type="bibr">29</xref>,<xref rid="B30-molecules-30-03628" ref-type="bibr">30</xref>].</p><p>Protection against neurodegeneration offered by IPA, particularly during high oxidative stress, inflammation, and in the processes linked to the abnormal aggregation of proteins, was demonstrated in various experimental paradigms [<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>,<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B42-molecules-30-03628" ref-type="bibr">42</xref>,<xref rid="B130-molecules-30-03628" ref-type="bibr">130</xref>].</p><p>In HT22 cells, an immortalized murine hippocampal cell line, IPA reduced apoptosis and oxidative damage caused by lipopolysaccharide (LPS) [<xref rid="B131-molecules-30-03628" ref-type="bibr">131</xref>]. It also decreased neuroinflammation by inhibiting the receptor for advanced glycation end-product (RAGE)/JAK2/STAT3 signaling pathway in LPS-treated BV2 cells, a murine microglial cell line [<xref rid="B131-molecules-30-03628" ref-type="bibr">131</xref>]. This pathway is associated with neuronal injury, inflammatory responses, and oxidative stress [<xref rid="B132-molecules-30-03628" ref-type="bibr">132</xref>,<xref rid="B133-molecules-30-03628" ref-type="bibr">133</xref>]. IPA derivatives demonstrated neuroprotective and antioxidant activities and inhibited MAO-B in SH-SY5Y neuroblastoma cells [<xref rid="B36-molecules-30-03628" ref-type="bibr">36</xref>].</p><sec id="sec4dot1-molecules-30-03628"><title>4.1. Alzheimer&#8217;s Disease (AD)</title><p>AD, the major cause of dementia in the elderly, is predicted to affect 150 million people worldwide by the year 2050 [<xref rid="B134-molecules-30-03628" ref-type="bibr">134</xref>]. It is characterized by the progressive accumulation of A&#946; in amyloid plaques in the brain and vasculature, and by deposits of hyperphosphorylated tau protein within neurons, neurofibrillary tangles, and increasing loss of neurons and cognitive abilities [<xref rid="B135-molecules-30-03628" ref-type="bibr">135</xref>,<xref rid="B136-molecules-30-03628" ref-type="bibr">136</xref>]. The social and economic costs of disease are tremendous, and, despite our increasing understanding of the underlying mechanism, currently available therapeutic options are merely symptomatic. Novel drugs introduced to therapy and targeting amyloid plaques, such as lecanemab and donanemab, offer moderate improvement in the brain pathology and cognition at the early stage of the disease; furthermore, they are linked with several serious adverse effects [<xref rid="B137-molecules-30-03628" ref-type="bibr">137</xref>].</p><p>The role of gut dysbiosis in the development of AD was the subject of numerous studies, presented in recent reviews [<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>,<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B138-molecules-30-03628" ref-type="bibr">138</xref>]. Experimental data support the view of IPA as beneficial in AD. The initial discovery came from studies in neuroblastoma cells and in neuronal primary cultures, in which IPA prevented oxidative stress and inhibited A&#946;-induced cell death [<xref rid="B35-molecules-30-03628" ref-type="bibr">35</xref>]. In neuroblastoma cells expressing the human APP gene, IPA increased mitochondrial membrane potential and respiration rate, and reduced free radical production [<xref rid="B138-molecules-30-03628" ref-type="bibr">138</xref>]. Recently, in silico and in vitro research demonstrated that esters of IPA inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities, which are pharmacological targets in AD [<xref rid="B139-molecules-30-03628" ref-type="bibr">139</xref>,<xref rid="B140-molecules-30-03628" ref-type="bibr">140</xref>].</p><p>IPA reduced A&#946; fibril formation by 50% and reduced the stimulatory effect of apolipoprotein E4 (ApoE4), measured by fluorescence intensity (unpublished observation of Pappolla et al. cited in a review by [<xref rid="B141-molecules-30-03628" ref-type="bibr">141</xref>]). Melatonin, a compound structurally similar to IPA, exerts corresponding effects, as it reverses the generation of neurofibrillary tangles evoked by ApoE4 on A&#946; [<xref rid="B142-molecules-30-03628" ref-type="bibr">142</xref>]. Both IPA and melatonin were demonstrated to improve mitochondrial respiratory rate in APP-expressing neuroblastoma cells [<xref rid="B138-molecules-30-03628" ref-type="bibr">138</xref>]. Melatonin has antioxidant properties, augments A&#946; clearance by the lymphatic system, and decreases oligomeric A&#946;40 in the brain [<xref rid="B3-molecules-30-03628" ref-type="bibr">3</xref>,<xref rid="B143-molecules-30-03628" ref-type="bibr">143</xref>,<xref rid="B144-molecules-30-03628" ref-type="bibr">144</xref>]. The effect of both IPA and melatonin is cumulative when it comes to preventing lipid peroxidation [<xref rid="B145-molecules-30-03628" ref-type="bibr">145</xref>].</p><p>In vivo, a strong positive correlation was observed between the levels of IPA generated by gut microbiota and behavioral changes in the 5xFAD transgenic AD mouse model [<xref rid="B44-molecules-30-03628" ref-type="bibr">44</xref>]. A 30-day treatment with <italic toggle="yes">Clostridium sporogenes</italic> improved cognitive performance and spatial memory, restored the synaptic ultrastructure and attenuated neuroinflammatory responses, and reduced cortical and hippocampal A&#946; accumulation. Concomitant increase in IPA levels, the relative prevalence of IPA-synthesizing bacteria in the gut, and a decrease in bacteria characteristic for AD, e.g., <italic toggle="yes">Aquabacterium</italic>, <italic toggle="yes">Corynebacterium</italic>, and <italic toggle="yes">Romboutsia,</italic> were shown [<xref rid="B44-molecules-30-03628" ref-type="bibr">44</xref>]. In transgenic APP/PS1 mice fed a Trp-free diet and treated orally with indole, IAA, and IPA for 4 weeks, a prominent reduction in inflammatory markers was observed. Upregulated AhR, inhibition of the NF-&#954;B pathway, and decreased formation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, reduced the levels of TNF-&#945;, IL-6, IL-1&#946;, and IL-18, and alleviated the inflammatory response, were all observed [<xref rid="B43-molecules-30-03628" ref-type="bibr">43</xref>]. IPA also ameliorated cognitive deficits and neuroinflammation in LPS-treated mice, possibly by inhibition of the RAGE/JAK2/STAT3 signaling pathway [<xref rid="B131-molecules-30-03628" ref-type="bibr">131</xref>]. In the murine APP/PS1 AD model, IPA was shown to interact with peroxisome proliferator-activated receptor &#945; (PPAR&#945;) and to activate neuroprotective genes, i.e., <italic toggle="yes">Bdnf</italic>, <italic toggle="yes">Ppar</italic>&#945;, <italic toggle="yes">acyl-CoA synthetase, bubblegum family, member 1 (Acsbg1)</italic>, <italic toggle="yes">stearoyl-CoA desaturase 2 (Scd2)</italic>, and <italic toggle="yes">Scd3</italic> [<xref rid="B45-molecules-30-03628" ref-type="bibr">45</xref>]. In male mice, increased abundance of indole-producing bacteria <italic toggle="yes">Lactobacillus reuteri,</italic> elevated levels of IPA, and enhanced PPAR&#945; signaling were linked an improvement of working memory and reduction of neuronal damage [<xref rid="B45-molecules-30-03628" ref-type="bibr">45</xref>]. Tetradecyl 2,3-dihydroxybenzoate (ABG-001), a molecule with NGF-mimicking activity and anti-aging properties, enhanced the production of IPA by gut microbiota in a murine model of AD. In this study, IPA was shown to target the heat shock cognate 70 kDa protein (Hsc70) and regulate the signaling pathways Hsc70/pyruvate kinase muscle isozyme/hexokinase 2/light chain 3 (PKM2/HK2/LC3) and forkhead box O3/sirtuin 1 (FOXO3a/SIRT1). ABG-001 diminished the memory dysfunctions of the experimental animals by modulating inflammation through IPA and autophagy via Hsc70 [<xref rid="B46-molecules-30-03628" ref-type="bibr">46</xref>]. Intermittent fasting, increasingly recognized as cardioprotective, neuroprotective, and promoting longer life span, was shown to improve mitochondrial bioenergetics, and to reverse cognitive deficits in diabetic mice. Alterations in microbial metabolites included an increase in IPA levels [<xref rid="B47-molecules-30-03628" ref-type="bibr">47</xref>]. Furthermore, the effects of intermittent fasting were mimicked by intraperitoneal administration of IPA [<xref rid="B47-molecules-30-03628" ref-type="bibr">47</xref>].</p><p>To our knowledge, just one study reported contrasting results. In patients with mild cognitive impairment, metabolomics and in silico studies suggested that the IPA level is a predictor of progression to AD. However, the trend towards increased plasma IPA was statistically insignificant, and the conclusion was based on the model constructed with the use of eight metabolites [<xref rid="B58-molecules-30-03628" ref-type="bibr">58</xref>].</p><p>In 2002, IPA was suggested as a promising therapeutic agent in AD [<xref rid="B141-molecules-30-03628" ref-type="bibr">141</xref>]. Plans for pre-clinical and clinical studies were also mentioned [<xref rid="B141-molecules-30-03628" ref-type="bibr">141</xref>]; however, no data about such clinical trials are available. In a recent review, the authors proposed that the health of the aging brain can be promoted, and dementia development may be prevented by inducing a higher production of indoles, such as IPA, by the microbiota [<xref rid="B2-molecules-30-03628" ref-type="bibr">2</xref>].</p></sec><sec id="sec4dot2-molecules-30-03628"><title>4.2. Parkinson&#8217;s Disease (PD)</title><p>PD is the second most prevalent neurodegenerative disorder [<xref rid="B146-molecules-30-03628" ref-type="bibr">146</xref>]. The accumulation and toxic aggregates of &#945;-synuclein and the degeneration of dopaminergic neurons in the substantia nigra are hallmarks of the disease [<xref rid="B147-molecules-30-03628" ref-type="bibr">147</xref>,<xref rid="B148-molecules-30-03628" ref-type="bibr">148</xref>,<xref rid="B149-molecules-30-03628" ref-type="bibr">149</xref>]. Genetic and environmental factors, which result in oxidative stress, decreased antioxidant capacity, neuroinflammation, lipid peroxidation, mitochondrial dysfunction, and pathological aggregation of &#945;-synuclein, have been implicated in PD pathogenesis [<xref rid="B149-molecules-30-03628" ref-type="bibr">149</xref>,<xref rid="B150-molecules-30-03628" ref-type="bibr">150</xref>,<xref rid="B151-molecules-30-03628" ref-type="bibr">151</xref>,<xref rid="B152-molecules-30-03628" ref-type="bibr">152</xref>].</p><p>Therapeutic options are symptomatic and involve enhancement of central dopaminergic transmission and acetylcholinesterase inhibitors (AChE-I) [<xref rid="B153-molecules-30-03628" ref-type="bibr">153</xref>]. Increasing evidence implies gut microbiota as a potential therapeutic target in PD [<xref rid="B64-molecules-30-03628" ref-type="bibr">64</xref>,<xref rid="B154-molecules-30-03628" ref-type="bibr">154</xref>].</p><p>IPA has been demonstrated to act as a chemical chaperone, reducing endoplasmic reticulum (ER) stress in cells that overexpress Parkin-associated endothelin-like receptor (GPR37) and &#945;-synuclein, thus modeling PD [<xref rid="B42-molecules-30-03628" ref-type="bibr">42</xref>]. IPA derivatives demonstrated neuroprotective and antioxidant activities in neuroblastoma cells and inhibited MAO-B, an enzyme that oxidizes dopamine, thus depleting its level and generating free radicals [<xref rid="B36-molecules-30-03628" ref-type="bibr">36</xref>]. Furthermore, IPA esters were shown to inhibit the AChE and BChE activities [<xref rid="B139-molecules-30-03628" ref-type="bibr">139</xref>]. In rotenone-stimulated enteric glial cells, IPA, in a PXR-mediated manner, reduced mRNA expression of IL-6, IL-1<italic toggle="yes">&#946;</italic>, and TNF-<italic toggle="yes">&#945;</italic>, impaired IL13 signaling with subsequent decline of JAK1-STAT6 pathway [<xref rid="B37-molecules-30-03628" ref-type="bibr">37</xref>]. The protective effects of IPA were also evident in vivo, in a rotenone model of PD in mice, where IPA alleviated enteric gliosis and restored the integrity of the intestinal and brain barriers [<xref rid="B37-molecules-30-03628" ref-type="bibr">37</xref>].</p><p>A study on 56 PD patients revealed surprisingly higher IPA levels in the plasma compared to controls (1.26 vs. 0.83 &#956;M); however, IPA did not correlate with cognitive and motor status scores of the patients [<xref rid="B27-molecules-30-03628" ref-type="bibr">27</xref>]. Furthermore, the analyses were not performed separately for patients with early (N = 19) and advanced (N = 37) disease, and the impact of medications and diet was not taken into consideration [<xref rid="B27-molecules-30-03628" ref-type="bibr">27</xref>]. The elevation of plasma IPA in PD patients could be a compensatory protective mechanism.</p></sec><sec id="sec4dot3-molecules-30-03628"><title>4.3. Hypoxia/Ischemia</title><p>IPA may also protect the brain after hypoxia and ischemia, as has been shown in several studies. IPA had a protective effect on the disruption of the blood&#8211;brain barrier following hypoxic-ischemic brain injury in neonatal rats, possibly by modulating the PXR signaling pathway [<xref rid="B39-molecules-30-03628" ref-type="bibr">39</xref>]. Indeed, its protective effects were reversed by PXR antagonists [<xref rid="B39-molecules-30-03628" ref-type="bibr">39</xref>]. In this study, IPA alleviated inflammation by inhibiting the NF-&#954;B pathway. This, in turn, reduced the brain injury-evoked expression of inducible nitric oxide synthase (iNOS), TNF-&#945;, IL-6, and IL-1&#946;, and decreased intracellular ROS levels. PXR overexpression in the rat brain microvascular endothelial cells ameliorated the decline in junctional proteins expression. Furthermore, it reduced the activity of the NF-&#954;B pathway in the model of oxygen-glucose deprivation injury. Additionally, IPA downregulated the activation of MMPs in rat brain microvascular endothelial cells [<xref rid="B39-molecules-30-03628" ref-type="bibr">39</xref>].</p><p>In a study on Mongolian gerbils, 2-week oral pretreatment with IPA reduced hippocampal CA1 damage by 50%, decreased expression of proinflammatory markers, and ameliorated DNA damage in pyramidal cells [<xref rid="B30-molecules-30-03628" ref-type="bibr">30</xref>]. In a murine model of middle cerebral artery occlusion (MCAO), post-stroke intragastric IPA ameliorated neuroinflammation and neuronal damage [<xref rid="B48-molecules-30-03628" ref-type="bibr">48</xref>]. It also improved the composition of gut microbiome with subsequent recovery of intestinal permeability and modulated the activity of regulatory T (Treg) and T helper 17 (Th17) cells in intestinal lymphoid tissue [<xref rid="B48-molecules-30-03628" ref-type="bibr">48</xref>]. Boosting microbial IPA production by acupuncture exerted beneficial effects in a glucose/oxygen deprivation model [<xref rid="B155-molecules-30-03628" ref-type="bibr">155</xref>].</p><p>A clinical study on 197 patients with acute cerebral infarction revealed that low serum IPA is an independent predictor of acute stroke and poor prognosis [<xref rid="B59-molecules-30-03628" ref-type="bibr">59</xref>]. In line with this report, it was recently discovered that mice bacterial phyla, known to generate AHR ligands, are significantly reduced by aging and experimental stroke. Furthermore, in the middle cerebral artery occlusion stroke model, a decreased serum IPA in mice was observed [<xref rid="B49-molecules-30-03628" ref-type="bibr">49</xref>]. Conversely, IPA treatment reduced the expression of IL-1&#946;, IL&#8722;4, and IL-10 in microglial cells exposed to oxygen-glucose deprivation. In the same study it was shown that, in patients suffering from stroke, plasma IPA was decreased up to 7 days after the event [<xref rid="B49-molecules-30-03628" ref-type="bibr">49</xref>].</p></sec><sec id="sec4dot4-molecules-30-03628"><title>4.4. Other Disorders</title><p>To our knowledge, there is only a single report on IPA status in patients with HD. The study included patients with premanifest (N = 52) and early symptomatic (N = 102) HD. Plasma IPA levels were decreased in both groups, reaching 138.5 ng/mL and 107.7 ng/mL, respectively, vs. control (191.1 ng/mL; N = 140) [<xref rid="B25-molecules-30-03628" ref-type="bibr">25</xref>].</p><p>The data on the role of IPA in multiple sclerosis are ambiguous. An increased IPA synthesis was observed in the relapsing&#8211;remitting experimental autoimmune encephalomyelitis in mice, considered a multiple sclerosis model [<xref rid="B156-molecules-30-03628" ref-type="bibr">156</xref>]. Similarly, higher IPA was observed by others in patients with the relapsing&#8211;remitting course of multiple sclerosis [<xref rid="B60-molecules-30-03628" ref-type="bibr">60</xref>]. Furthermore, Expanded Disability Status Scale (EDSS) scores, demonstrating the disability level in patients with multiple sclerosis, were significantly correlated with the urine concentration of IPA (r = 0.5, <italic toggle="yes">p</italic> &lt; 0.001) [<xref rid="B60-molecules-30-03628" ref-type="bibr">60</xref>]. On the other hand, activation of astrocytic AHR by IPA was shown to reduce the central nervous system inflammation and to decrease immune-mediated damage in experimental autoimmune encephalomyelitis [<xref rid="B54-molecules-30-03628" ref-type="bibr">54</xref>].</p><p>IPA&#8217;s protective properties were observed in models of autism spectrum disorder. IPA deficiency disrupts the IPA/AHR/NF-&#954;B signaling pathway, resulting in the overactivation of hippocampal microglia and excessive pruning of neuronal synapses. This dysregulation is associated with neural patterns and behaviors similar to those observed in autism spectrum disorder [<xref rid="B52-molecules-30-03628" ref-type="bibr">52</xref>].</p><p>IPA was also found to promote axon regeneration and functional recovery after sciatic nerve crush in mice [<xref rid="B56-molecules-30-03628" ref-type="bibr">56</xref>]. Administration of IPA for 10 days before injury and up to the third day after injury enhanced axonal regeneration and the recovery of sensory function. IPA increased the expression of the PXR gene and genes involved in neutrophil chemotaxis, thereby regulating the regenerative capacity of dorsal root ganglia. Moreover, the inhibition of neutrophil chemotaxis prevented IPA-mediated axonal regeneration [<xref rid="B56-molecules-30-03628" ref-type="bibr">56</xref>].</p><p>In a rat traumatic brain injury model, the serum levels of IPA exhibited an initial downward trend, which became reversed after three days [<xref rid="B57-molecules-30-03628" ref-type="bibr">57</xref>]. These results suggested that IPA may serve to monitor the time that elapsed from the injury [<xref rid="B57-molecules-30-03628" ref-type="bibr">57</xref>].</p><p>Research on the potential beneficial effects of IPA in aging revealed that elevated IPA levels were associated with an increase in serum BDNF in healthy elderly subjects [<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>].</p></sec></sec><sec sec-type="conclusions" id="sec5-molecules-30-03628"><title>5. Conclusions</title><p>It is generally well established that administration of IPA to experimental animals or humans is not associated with significant adverse effects. In contrast to other antioxidants, the advantage of IPA is that it does not exhibit pro-oxidant activity, as it does not undergo decarboxylation of the side chain to produce reactive peroxy-radicals [<xref rid="B157-molecules-30-03628" ref-type="bibr">157</xref>]. IPA generated as part of normal metabolism, at physiological levels, primarily exerts no cytotoxic effect [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B138-molecules-30-03628" ref-type="bibr">138</xref>,<xref rid="B158-molecules-30-03628" ref-type="bibr">158</xref>]. The lack of toxicity in neuroblastoma cells was shown up to 500 &#956;M [<xref rid="B36-molecules-30-03628" ref-type="bibr">36</xref>]. Furthermore, IPA derivative was shown to extend life span in experimental animals and exert protective effects in various models, ranging from cell loss due to cytostatic use through myocardial fibrosis up to brain neurodegeneration [<xref rid="B10-molecules-30-03628" ref-type="bibr">10</xref>,<xref rid="B91-molecules-30-03628" ref-type="bibr">91</xref>]. It seems of interest, though, that IPA in high doses may inhibit the growth of some neoplastic cells [<xref rid="B159-molecules-30-03628" ref-type="bibr">159</xref>].</p><p>However, IPA acts as a plant auxin and can be enriched in a variety of vegetables and fruits, with the consequences for humans not fully understood [<xref rid="B160-molecules-30-03628" ref-type="bibr">160</xref>]. AhR is crucial in prenatal development, but, on the other hand, it was implicated in age-related pathologies [<xref rid="B161-molecules-30-03628" ref-type="bibr">161</xref>]. Furthermore, AhR may control cellular fate by acting as a neurogenesis-promoting factor. However, it may also be linked with morphological and functional brain changes during aging [<xref rid="B162-molecules-30-03628" ref-type="bibr">162</xref>,<xref rid="B163-molecules-30-03628" ref-type="bibr">163</xref>].</p><p>Prolonged excessive AhR stimulation was related to oncogenic potential. Gastric glandular epithelial tumors in mice with constitutively active AhR were reported [<xref rid="B164-molecules-30-03628" ref-type="bibr">164</xref>]. In contrast, IPA itself does not seem to contribute to tumor development. In fact, the cytostatic properties of IPA, related to the activation of AhR and PXR, were demonstrated, further supporting the beneficial effects of IPA administration [<xref rid="B165-molecules-30-03628" ref-type="bibr">165</xref>]. Thus, the contribution of AhR to IPA action requires further studies, especially in the context of potential adverse effects of long-term therapy.</p><p>According to the ClinicalTrial.gov database, three studies aimed to evaluate the effects of IPA in humans. Single or chronic oral administration of IPA (150 mg) was examined in patients with Friedreich&#8217;s ataxia, and no toxic effects were noted [<xref rid="B166-molecules-30-03628" ref-type="bibr">166</xref>]. Another study on the toxicity of IPA, Indole-3-PROpionic Acid Clinical Trials-a Pilot Study (iPROACT-pilot), was recently finished, but no results have been posted yet [<xref rid="B167-molecules-30-03628" ref-type="bibr">167</xref>]. The third trial, Tryptophan for Impaired AhR Signaling in Celiac Disease (TIARSCeD), is currently ongoing [<xref rid="B168-molecules-30-03628" ref-type="bibr">168</xref>].</p><p>Microbiota-generated IPA displays pleiotropic effects associated with its ability to target AhR and PXR, to ameliorate the inflammation, and reduce free radical toxicity. The beneficial outcome of experimental IPA administration in AD, PD, and stroke models is well substantiated. Nutritional factors, specifically a low-fat, high-fiber, high-carbohydrate, and Trp-rich diet, along with probiotic supplementation, may enhance gut IPA synthesis. Thus, a well-planned diet may be beneficial in the course of neurodegeneration, considering its effect on IPA and the gut&#8211;brain axis.</p><sec><title>Future Directions</title><p>There are still a number of unanswered questions concerning IPA action. The majority of data implicate the beneficial effects of IPA, yet some findings warrant further research. It is not clear whether IPA will offer clinical improvement in multiple sclerosis. Furthermore, the contribution of AhR activity to neuronal survival should be studied in more detail, including potentially confounding factors such as diet composition, microbiome variability, and pharmacokinetics of the compound. Similarly, the impact of IPA on KYNA synthesis must be clarified. Currently, it is not understood what intestinal factors are necessary to stimulate the generation of KYNA, and whether they are of microbial or intestinal origin.</p><p>In view of the accumulated data and considering a huge demand for novel neuroprotective compounds, clinical trials evaluating the potential use of IPA are essential. We suggest that IPA should be evaluated as (1) a preventive measure aimed to delay the onset of AD- and PD-related neurodegeneration and cognitive impairment in high-risk populations, (2) a therapeutic add-on intervention aimed to slow down the progress of AD and PD, and (3) a therapeutic approach aimed to limit the morphological and behavioral consequences of ischemic stroke. Further experimental and clinical research should also bring more details on the prospective use of IPA in other clinical conditions associated with neuronal loss.</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, E.M.U. and M.C.; writing&#8212;original draft preparation, M.O.-L., D.D., P.I. and R.K.; writing&#8212;review and editing, E.M.U. and M.C.; graphic work, M.O.-L. and D.D.; supervision, E.M.U. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">3-HK </td><td align="left" valign="middle" rowspan="1" colspan="1">3-hydroxykynurenine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ABG-001 </td><td align="left" valign="middle" rowspan="1" colspan="1">tetradecyl 2,3-dihydroxybenzoate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">acdA</td><td align="left" valign="middle" rowspan="1" colspan="1">acyl-coenzyme A dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AChE </td><td align="left" valign="middle" rowspan="1" colspan="1">acetylcholinesterase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACSBG1 </td><td align="left" valign="middle" rowspan="1" colspan="1">acyl-CoA synthetase, bubblegum family, member 1 gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AD </td><td align="left" valign="middle" rowspan="1" colspan="1">Alzheimer&#8217;s disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADRA2B </td><td align="left" valign="middle" rowspan="1" colspan="1">adrenoceptor alpha 2B</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AhR </td><td align="left" valign="middle" rowspan="1" colspan="1">aryl hydrocarbon receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Apo-E4 </td><td align="left" valign="middle" rowspan="1" colspan="1">apolipoprotein E4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APP </td><td align="left" valign="middle" rowspan="1" colspan="1">amyloid-beta precursor protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ArAT </td><td align="left" valign="middle" rowspan="1" colspan="1">aromatic amino acid aminotransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">A&#946; </td><td align="left" valign="middle" rowspan="1" colspan="1">&#946;-amyloid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BBB </td><td align="left" valign="middle" rowspan="1" colspan="1">blood&#8211;brain barrier</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BChE </td><td align="left" valign="middle" rowspan="1" colspan="1">butyrylcholinesterase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BDNF: </td><td align="left" valign="middle" rowspan="1" colspan="1">brain-derived neurotrophic factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CSF </td><td align="left" valign="middle" rowspan="1" colspan="1">cerebrospinal fluid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP1A1 </td><td align="left" valign="middle" rowspan="1" colspan="1">cytochrome P450, family 1, subfamily A, polypeptide 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CYP3A </td><td align="left" valign="middle" rowspan="1" colspan="1">cytochrome P450, family 3, subfamily A</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">half maximal effective concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECM </td><td align="left" valign="middle" rowspan="1" colspan="1">extracellular matrix</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EDSS </td><td align="left" valign="middle" rowspan="1" colspan="1">Expanded Disability Status Scale</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">fldBC </td><td align="left" valign="middle" rowspan="1" colspan="1">phenyllactate dehydratase BC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FOXO3a </td><td align="left" valign="middle" rowspan="1" colspan="1">forkhead box O3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPR</td><td align="left" valign="middle" rowspan="1" colspan="1">G-protein-coupled receptor </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCAR3 </td><td align="left" valign="middle" rowspan="1" colspan="1">hydroxycarboxylic acid receptor 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HD </td><td align="left" valign="middle" rowspan="1" colspan="1">Huntington&#8217;s disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HK2 </td><td align="left" valign="middle" rowspan="1" colspan="1">hexokinase 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hsc70 </td><td align="left" valign="middle" rowspan="1" colspan="1">heat shock cognate 70 kDa protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IA</td><td align="left" valign="middle" rowspan="1" colspan="1">indoleacrylic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IAA </td><td align="left" valign="middle" rowspan="1" colspan="1">indole-3-acetic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IDO1 </td><td align="left" valign="middle" rowspan="1" colspan="1">indoleamine 2,3-dioxygenase 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFN-&#947; </td><td align="left" valign="middle" rowspan="1" colspan="1">interferon gamma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-1&#946;/4/6/10 </td><td align="left" valign="middle" rowspan="1" colspan="1">interleukin 1&#946;/4/6/10</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL4I1 </td><td align="left" valign="middle" rowspan="1" colspan="1">interleukin 4-induced 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ILA</td><td align="left" valign="middle" rowspan="1" colspan="1">indolelactic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ILDH</td><td align="left" valign="middle" rowspan="1" colspan="1">indole-lactate dehydrogenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iNOS </td><td align="left" valign="middle" rowspan="1" colspan="1">inducible nitric oxide synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IPA</td><td align="left" valign="middle" rowspan="1" colspan="1">indole-3-propionic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IPAM </td><td align="left" valign="middle" rowspan="1" colspan="1">indolepropionamide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">iPROACT-pilot</td><td align="left" valign="middle" rowspan="1" colspan="1">Indole-3-PROpionic Acid Clinical Trials-a Pilot Study</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IPyA</td><td align="left" valign="middle" rowspan="1" colspan="1">indole-3-pyruvic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">JAK1/2 </td><td align="left" valign="middle" rowspan="1" colspan="1">Janus kinase 1/2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KATs </td><td align="left" valign="middle" rowspan="1" colspan="1">kynurenine aminotransferases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KMO </td><td align="left" valign="middle" rowspan="1" colspan="1">kynurenine 3-monooxygenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KP </td><td align="left" valign="middle" rowspan="1" colspan="1">kynurenine pathway</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KYNA </td><td align="left" valign="middle" rowspan="1" colspan="1">kynurenic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC3 </td><td align="left" valign="middle" rowspan="1" colspan="1">light chain 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPS </td><td align="left" valign="middle" rowspan="1" colspan="1">lipopolysaccharide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAO</td><td align="left" valign="middle" rowspan="1" colspan="1">monoamino-oxidase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCAO </td><td align="left" valign="middle" rowspan="1" colspan="1">middle cerebral artery occlusion</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCP-1/CCL2 </td><td align="left" valign="middle" rowspan="1" colspan="1">monocyte chemoattractant protein-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMP </td><td align="left" valign="middle" rowspan="1" colspan="1">matrix metalloproteinase;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NAD </td><td align="left" valign="middle" rowspan="1" colspan="1">nicotinamide adenine dinucleotide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NF-&#954;B </td><td align="left" valign="middle" rowspan="1" colspan="1">nuclear factor kappa-light-chain-enhancer of activated B cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGF </td><td align="left" valign="middle" rowspan="1" colspan="1">nerve growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NLRP3 </td><td align="left" valign="middle" rowspan="1" colspan="1">NLR family pyrin domain containing 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMDA </td><td align="left" valign="middle" rowspan="1" colspan="1">N-methyl-D-aspartate type</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NR1I2 </td><td align="left" valign="middle" rowspan="1" colspan="1">nuclear receptor subfamily 1 group I member 2 gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Oatp1a4 </td><td align="left" valign="middle" rowspan="1" colspan="1">organic anion-transporting polypeptide 1a4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD </td><td align="left" valign="middle" rowspan="1" colspan="1">Parkinson&#8217;s disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PKM2 </td><td align="left" valign="middle" rowspan="1" colspan="1">pyruvate kinase muscle isozyme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PPAR&#945; </td><td align="left" valign="middle" rowspan="1" colspan="1">peroxisome proliferator-activated receptor &#945;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PXR </td><td align="left" valign="middle" rowspan="1" colspan="1">pregnane X receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">QUIN </td><td align="left" valign="middle" rowspan="1" colspan="1">quinolinic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RAGE </td><td align="left" valign="middle" rowspan="1" colspan="1">receptor for advanced glycation end-products</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS </td><td align="left" valign="middle" rowspan="1" colspan="1">reactive oxygen species</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SCD2/3 </td><td align="left" valign="middle" rowspan="1" colspan="1">stearoyl-CoA desaturase 2/3 gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SIRT1 </td><td align="left" valign="middle" rowspan="1" colspan="1">sirtuin 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">STAT3/6 </td><td align="left" valign="middle" rowspan="1" colspan="1">signal transducer and activator of transcription 3/6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAA </td><td align="left" valign="middle" rowspan="1" colspan="1">Trp aminotransferase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TDO </td><td align="left" valign="middle" rowspan="1" colspan="1">tryptophan 2,3-dioxygenase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-1 </td><td align="left" valign="middle" rowspan="1" colspan="1">transforming growth factor &#946;1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Th17 </td><td align="left" valign="middle" rowspan="1" colspan="1">T helper 17 cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TIARSCeD </td><td align="left" valign="middle" rowspan="1" colspan="1">Tryptophan for Impaired AhR Signaling in Celiac Disease</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLRs </td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#945; </td><td align="left" valign="middle" rowspan="1" colspan="1">tumor necrosis factor-&#945;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Treg </td><td align="left" valign="middle" rowspan="1" colspan="1">regulatory T cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Trp </td><td align="left" valign="middle" rowspan="1" colspan="1">tryptophan</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#945;7nAChR </td><td align="left" valign="middle" rowspan="1" colspan="1">&#945;-7 nicotinic acetylcholine receptor</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-molecules-30-03628"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negatu</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Gengenbacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dartois</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>T.</given-names></name></person-group><article-title>Indole Propionic Acid, an Unusual Antibiotic Produced by the Gut Microbiota, with Anti-inflammatory and Antioxidant Properties</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><elocation-id>575586</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.575586</pub-id><pub-id pub-id-type="pmid">33193190</pub-id><pub-id pub-id-type="pmcid">PMC7652848</pub-id></element-citation></ref><ref id="B2-molecules-30-03628"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zagorski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sambamurti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name></person-group><article-title>Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer&#8217;s disease</article-title><source>Neurobiol. Dis.</source><year>2021</year><volume>156</volume><elocation-id>105403</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2021.105403</pub-id><pub-id pub-id-type="pmid">34087380</pub-id></element-citation></ref><ref id="B3-molecules-30-03628"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konopelski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mogilnicka</surname><given-names>I.</given-names></name></person-group><article-title>Biological Effects of Indole-3-Propionic Acid, a Gut Microbiota-Derived Metabolite, and Its Precursor Tryptophan in Mammals&#8217; Health and Disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>1222</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031222</pub-id><pub-id pub-id-type="pmid">35163143</pub-id><pub-id pub-id-type="pmcid">PMC8835432</pub-id></element-citation></ref><ref id="B4-molecules-30-03628"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name></person-group><article-title>The gut microbiota-derived metabolite indole-3-propionic acid enhances leptin sensitivity by targeting STAT3 against diet-induced obesity</article-title><source>Clin. Transl. Med.</source><year>2024</year><volume>14</volume><fpage>e70053</fpage><pub-id pub-id-type="doi">10.1002/ctm2.70053</pub-id><pub-id pub-id-type="pmid">39606796</pub-id><pub-id pub-id-type="pmcid">PMC11602751</pub-id></element-citation></ref><ref id="B5-molecules-30-03628"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>S.S.</given-names></name></person-group><article-title>Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventions</article-title><source>Genome Med.</source><year>2016</year><volume>8</volume><fpage>46</fpage><pub-id pub-id-type="doi">10.1186/s13073-016-0296-x</pub-id><pub-id pub-id-type="pmid">27102537</pub-id><pub-id pub-id-type="pmcid">PMC4840492</pub-id></element-citation></ref><ref id="B6-molecules-30-03628"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Farzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.Y.</given-names></name></person-group><article-title>Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain</article-title><source>Adv. Nutr.</source><year>2020</year><volume>11</volume><fpage>709</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1093/advances/nmz127</pub-id><pub-id pub-id-type="pmid">31825083</pub-id><pub-id pub-id-type="pmcid">PMC7231603</pub-id></element-citation></ref><ref id="B7-molecules-30-03628"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavlova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vidova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bienertova-Vasku</surname><given-names>J.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>P.</given-names></name><name name-style="western"><surname>Almasi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klanova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Spacil</surname><given-names>Z.</given-names></name></person-group><article-title>Urinary intermediates of tryptophan as indicators of the gut microbial metabolism</article-title><source>Anal. Chim. Acta</source><year>2017</year><volume>987</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.aca.2017.08.022</pub-id><pub-id pub-id-type="pmid">28916042</pub-id></element-citation></ref><ref id="B8-molecules-30-03628"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexeev</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Lanis</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kao</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Battista</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Gerich</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Walk</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Kominsky</surname><given-names>D.J.</given-names></name><etal/></person-group><article-title>Microbiota-Derived Indole Metabolites Promote Human and Murine Intestinal Homeostasis through Regulation of Interleukin-10 Receptor</article-title><source>Am. J. Pathol.</source><year>2018</year><volume>188</volume><fpage>1183</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2018.01.011</pub-id><pub-id pub-id-type="pmid">29454749</pub-id><pub-id pub-id-type="pmcid">PMC5906738</pub-id></element-citation></ref><ref id="B9-molecules-30-03628"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders</article-title><source>Front. Endocrinol.</source><year>2022</year><volume>13</volume><elocation-id>841703</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.841703</pub-id><pub-id pub-id-type="pmid">35370963</pub-id><pub-id pub-id-type="pmcid">PMC8972051</pub-id></element-citation></ref><ref id="B10-molecules-30-03628"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Extensive Summary of the Important Roles of Indole Propionic Acid, a Gut Microbial Metabolite in Host Health and Disease</article-title><source>Nutrients</source><year>2022</year><volume>15</volume><elocation-id>151</elocation-id><pub-id pub-id-type="doi">10.3390/nu15010151</pub-id><pub-id pub-id-type="pmid">36615808</pub-id><pub-id pub-id-type="pmcid">PMC9824871</pub-id></element-citation></ref><ref id="B11-molecules-30-03628"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name></person-group><article-title>Indole derivatives and their associated microbial genera are associated with the 1-year changes in cardiometabolic risk markers in Chinese adults</article-title><source>Nutr. J.</source><year>2024</year><volume>23</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.1186/s12937-024-01067-4</pub-id><pub-id pub-id-type="pmid">39731110</pub-id><pub-id pub-id-type="pmcid">PMC11681765</pub-id></element-citation></ref><ref id="B12-molecules-30-03628"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodd</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spitzer</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Van Treuren</surname><given-names>W.</given-names></name><name name-style="western"><surname>Merrill</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Hryckowian</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Higginbottom</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Le</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Fischbach</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites</article-title><source>Nature</source><year>2017</year><volume>551</volume><fpage>648</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1038/nature24661</pub-id><pub-id pub-id-type="pmid">29168502</pub-id><pub-id pub-id-type="pmcid">PMC5850949</pub-id></element-citation></ref><ref id="B13-molecules-30-03628"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roager</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Licht</surname><given-names>T.R.</given-names></name></person-group><article-title>Microbial tryptophan catabolites in health and disease</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3294</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05470-4</pub-id><pub-id pub-id-type="pmid">30120222</pub-id><pub-id pub-id-type="pmcid">PMC6098093</pub-id></element-citation></ref><ref id="B14-molecules-30-03628"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Young</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Purdy</surname><given-names>W.C.</given-names></name></person-group><article-title>The origin of indoleacetic acid and indolepropionic acid in rat and human cerebrospinal fluid</article-title><source>J. Neurochem.</source><year>1980</year><volume>34</volume><fpage>1087</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1980.tb09944.x</pub-id><pub-id pub-id-type="pmid">6154772</pub-id></element-citation></ref><ref id="B15-molecules-30-03628"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheetham</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Mikloiche</surname><given-names>C.</given-names></name><name name-style="western"><surname>Glubiak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weathers</surname><given-names>P.</given-names></name></person-group><article-title>Micropropagation of a recalcitrant male asparagus clone (MD 22-8)</article-title><source>Plant Cell Tissue Organ Cult.</source><year>1992</year><volume>31</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/BF00043470</pub-id></element-citation></ref><ref id="B16-molecules-30-03628"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Vital</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mohney</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Valdes</surname><given-names>A.M.</given-names></name></person-group><article-title>Circulating levels of the anti-oxidant indoleproprionic acid are associated with higher gut microbiome diversity</article-title><source>Gut. Microbes.</source><year>2019</year><volume>10</volume><fpage>688</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1080/19490976.2019.1586038</pub-id><pub-id pub-id-type="pmid">31030641</pub-id><pub-id pub-id-type="pmcid">PMC6866703</pub-id></element-citation></ref><ref id="B17-molecules-30-03628"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>da Silva</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Marchesan</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Rampelotto</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Landberg</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Mello</surname><given-names>V.</given-names></name><name name-style="western"><surname>Spritzer</surname><given-names>P.M.</given-names></name></person-group><article-title>Gut microbiota and gut-derived metabolites are altered and associated with dietary intake in women with polycystic ovary syndrome</article-title><source>J. Ovarian Res.</source><year>2024</year><volume>17</volume><fpage>232</fpage><pub-id pub-id-type="doi">10.1186/s13048-024-01550-w</pub-id><pub-id pub-id-type="pmid">39578890</pub-id><pub-id pub-id-type="pmcid">PMC11583432</pub-id></element-citation></ref><ref id="B18-molecules-30-03628"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sawrey-Kubicek</surname><given-names>L.</given-names></name><name name-style="western"><surname>Beals</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Houts</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Sacchi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zivkovic</surname><given-names>A.M.</given-names></name></person-group><article-title>Human gut microbiome composition and tryptophan metabolites were changed differently by fast food and Mediterranean diet in 4 days: A pilot study</article-title><source>Nutr. Res.</source><year>2020</year><volume>77</volume><fpage>62</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2020.03.005</pub-id><pub-id pub-id-type="pmid">32330749</pub-id></element-citation></ref><ref id="B19-molecules-30-03628"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Mello</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Paananen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lindstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lankinen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kuusisto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pihlajam&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Auriola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lehtonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rolandsson</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>46337</elocation-id><pub-id pub-id-type="doi">10.1038/srep46337</pub-id><pub-id pub-id-type="pmid">28397877</pub-id><pub-id pub-id-type="pmcid">PMC5387722</pub-id></element-citation></ref><ref id="B20-molecules-30-03628"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Konop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Onyszkiewicz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Podsadni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szczepa&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tur&#322;o</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ufnal</surname><given-names>M.</given-names></name></person-group><article-title>Colonic indole, gut bacteria metabolite of tryptophan, increases portal blood pressure in rats</article-title><source>Am. J. Physiol. Regul. Integr. Comp. Physiol.</source><year>2018</year><volume>315</volume><fpage>R646</fpage><lpage>R655</lpage><pub-id pub-id-type="doi">10.1152/ajpregu.00111.2018</pub-id><pub-id pub-id-type="pmid">29847162</pub-id></element-citation></ref><ref id="B21-molecules-30-03628"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Tryptophan-Rich Diet Improves High-Fat Diet-Induced Cognitive Dysfunction and Blood-Brain Barrier Disruption in C57BL/6 Mice through FFAR3 Activation</article-title><source>J. Agric. Food Chem.</source><year>2025</year><volume>73</volume><fpage>17696</fpage><lpage>17712</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.5c05217</pub-id><pub-id pub-id-type="pmid">40600293</pub-id><pub-id pub-id-type="pmcid">PMC12273707</pub-id></element-citation></ref><ref id="B22-molecules-30-03628"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wikoff</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Anfora</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Lesley</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Siuzdak</surname><given-names>G.</given-names></name></person-group><article-title>Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>3698</fpage><lpage>3703</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812874106</pub-id><pub-id pub-id-type="pmid">19234110</pub-id><pub-id pub-id-type="pmcid">PMC2656143</pub-id></element-citation></ref><ref id="B23-molecules-30-03628"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>G.M.</given-names></name></person-group><article-title>The quantitative determination of indolic microbial tryptophan metabolites in human and rodent samples: A systematic review</article-title><source>J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.</source><year>2021</year><volume>1186</volume><elocation-id>123008</elocation-id><pub-id pub-id-type="doi">10.1016/j.jchromb.2021.123008</pub-id><pub-id pub-id-type="pmid">34735972</pub-id></element-citation></ref><ref id="B24-molecules-30-03628"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konopelski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Konop</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gawrys-Kopczynska</surname><given-names>M.</given-names></name><name name-style="western"><surname>Podsadni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szczepanska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ufnal</surname><given-names>M.</given-names></name></person-group><article-title>Indole-3-Propionic Acid, a Tryptophan-Derived Bacterial Metabolite, Reduces Weight Gain in Rats</article-title><source>Nutrients</source><year>2019</year><volume>11</volume><elocation-id>591</elocation-id><pub-id pub-id-type="doi">10.3390/nu11030591</pub-id><pub-id pub-id-type="pmid">30862081</pub-id><pub-id pub-id-type="pmcid">PMC6471155</pub-id></element-citation></ref><ref id="B25-molecules-30-03628"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosas</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Doros</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bhasin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gevorkian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malarick</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hersch</surname><given-names>S.M.</given-names></name></person-group><article-title>A systems-level &#8220;misunderstanding&#8221;: The plasma metabolome in Huntington&#8217;s disease</article-title><source>Ann. Clin. Transl. Neurol.</source><year>2015</year><volume>2</volume><fpage>756</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1002/acn3.214</pub-id><pub-id pub-id-type="pmid">26273688</pub-id><pub-id pub-id-type="pmcid">PMC4531058</pub-id></element-citation></ref><ref id="B26-molecules-30-03628"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuomainen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lindstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lehtonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auriola</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pihlajam&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peltonen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tuomilehto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uusitupa</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Mello</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Hanhineva</surname><given-names>K.</given-names></name></person-group><article-title>Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals</article-title><source>Nutr. Diabetes</source><year>2018</year><volume>8</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1038/s41387-018-0046-9</pub-id><pub-id pub-id-type="pmid">29795366</pub-id><pub-id pub-id-type="pmcid">PMC5968030</pub-id></element-citation></ref><ref id="B27-molecules-30-03628"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Liou</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.H.</given-names></name></person-group><article-title>Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson&#8217;s Disease</article-title><source>J. Park. Dis.</source><year>2022</year><volume>12</volume><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.3233/JPD-223179</pub-id><pub-id pub-id-type="pmid">35342048</pub-id></element-citation></ref><ref id="B28-molecules-30-03628"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hardeland</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rassoulpour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hodgkins</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Guidetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schwarcz</surname><given-names>R.</given-names></name></person-group><article-title>Indole-3-propionate: A potent hydroxyl radical scavenger in rat brain</article-title><source>Brain Res.</source><year>1999</year><volume>815</volume><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(98)01027-0</pub-id><pub-id pub-id-type="pmid">9878843</pub-id></element-citation></ref><ref id="B29-molecules-30-03628"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Manchester</surname><given-names>L.C.</given-names></name></person-group><article-title>Melatonin, hydroxyl radical-mediated oxidative damage, and aging: A hypothesis</article-title><source>J. Pineal Res.</source><year>1993</year><volume>14</volume><fpage>151</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079X.1993.tb00498.x</pub-id><pub-id pub-id-type="pmid">8102180</pub-id></element-citation></ref><ref id="B30-molecules-30-03628"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Y.G.</given-names></name><etal/></person-group><article-title>Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus</article-title><source>J. Neurosci. Res.</source><year>2009</year><volume>87</volume><fpage>2126</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1002/jnr.22030</pub-id><pub-id pub-id-type="pmid">19235887</pub-id></element-citation></ref><ref id="B31-molecules-30-03628"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sehgal</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Mello</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>M&#228;nnist&#246;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lindstr&#246;m</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tuomilehto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pihlajam&#228;ki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Uusitupa</surname><given-names>M.</given-names></name></person-group><article-title>Indolepropionic Acid, a Gut Bacteria-Produced Tryptophan Metabolite and the Risk of Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>4695</elocation-id><pub-id pub-id-type="doi">10.3390/nu14214695</pub-id><pub-id pub-id-type="pmid">36364957</pub-id><pub-id pub-id-type="pmcid">PMC9653718</pub-id></element-citation></ref><ref id="B32-molecules-30-03628"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>W.</given-names></name></person-group><article-title>Gut Microbially Produced Indole-3-Propionic Acid Inhibits Atherosclerosis by Promoting Reverse Cholesterol Transport and Its Deficiency Is Causally Related to Atherosclerotic Cardiovascular Disease</article-title><source>Circ. Res.</source><year>2022</year><volume>131</volume><fpage>404</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.321253</pub-id><pub-id pub-id-type="pmid">35893593</pub-id></element-citation></ref><ref id="B33-molecules-30-03628"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.M.</given-names></name></person-group><article-title>Gut microbiota indole-3-propionic acid mediates neuroprotective effect of probiotic consumption in healthy elderly: A randomized, double-blind, placebo-controlled, multicenter trial and in vitro study</article-title><source>Clin. Nutr.</source><year>2023</year><volume>42</volume><fpage>1025</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2023.04.001</pub-id><pub-id pub-id-type="pmid">37150125</pub-id></element-citation></ref><ref id="B34-molecules-30-03628"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathyasaikumar</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Blanco-Ayala</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schwieler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Erhardt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tufvesson-Alm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schwarcz</surname><given-names>R.</given-names></name></person-group><article-title>The Tryptophan Metabolite Indole-3-Propionic Acid Raises Kynurenic Acid Levels in the Rat Brain In Vivo</article-title><source>Int. J. Tryptophan Res.</source><year>2024</year><volume>17</volume><fpage>11786469241262876</fpage><pub-id pub-id-type="doi">10.1177/11786469241262876</pub-id><pub-id pub-id-type="pmid">38911967</pub-id><pub-id pub-id-type="pmcid">PMC11191616</pub-id></element-citation></ref><ref id="B35-molecules-30-03628"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chyan</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Chain</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ghiso</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name></person-group><article-title>Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>21937</fpage><lpage>21942</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.31.21937</pub-id><pub-id pub-id-type="pmid">10419516</pub-id></element-citation></ref><ref id="B36-molecules-30-03628"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anastassova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stefanova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hristova-Avakumova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Georgieva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kondeva-Burdina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rangelov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Todorova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tzoneva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yancheva</surname><given-names>D.</given-names></name></person-group><article-title>New Indole-3-Propionic Acid and 5-Methoxy-Indole Carboxylic Acid Derived Hydrazone Hybrids as Multifunctional Neuroprotectors</article-title><source>Antioxidants</source><year>2023</year><volume>12</volume><elocation-id>977</elocation-id><pub-id pub-id-type="doi">10.3390/antiox12040977</pub-id><pub-id pub-id-type="pmid">37107353</pub-id><pub-id pub-id-type="pmcid">PMC10135567</pub-id></element-citation></ref><ref id="B37-molecules-30-03628"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Microbial metabolite 3-indolepropionic acid alleviated PD pathologies by decreasing enteric glia cell gliosis via suppressing IL-13R&#945;1 related signaling pathways</article-title><source>Acta Pharm. Sin. B</source><year>2025</year><volume>15</volume><fpage>2024</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2025.02.029</pub-id><pub-id pub-id-type="pmid">40486846</pub-id><pub-id pub-id-type="pmcid">PMC12137974</pub-id></element-citation></ref><ref id="B38-molecules-30-03628"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Gut Microbiota-Derived Indole Derivatives Alleviate Neurodegeneration in Aging through Activating GPR30/AMPK/SIRT1 Pathway</article-title><source>Mol. Nutr. Food Res.</source><year>2023</year><volume>67</volume><fpage>e2200739</fpage><pub-id pub-id-type="doi">10.1002/mnfr.202200739</pub-id><pub-id pub-id-type="pmid">36823436</pub-id></element-citation></ref><ref id="B39-molecules-30-03628"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Indole-3-propionic Acid Attenuates HI-Related Blood-Brain Barrier Injury in Neonatal Rats by Modulating the PXR Signaling Pathway</article-title><source>ACS Chem. Neurosci.</source><year>2022</year><volume>13</volume><fpage>2897</fpage><lpage>2912</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.2c00418</pub-id><pub-id pub-id-type="pmid">36129348</pub-id></element-citation></ref><ref id="B40-molecules-30-03628"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbownik</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Soko&#322;owska</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kowalczyk</surname><given-names>E.</given-names></name></person-group><article-title>Gut Microbiota Metabolites Differentially Release Gliotransmitters from the Cultured Human Astrocytes: A Preliminary Report</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>6617</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24076617</pub-id><pub-id pub-id-type="pmid">37047602</pub-id><pub-id pub-id-type="pmcid">PMC10095279</pub-id></element-citation></ref><ref id="B41-molecules-30-03628"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcez</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>V.X.</given-names></name><name name-style="western"><surname>Heng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guillemin</surname><given-names>G.J.</given-names></name></person-group><article-title>Sodium Butyrate and Indole-3-propionic Acid Prevent the Increase of Cytokines and Kynurenine Levels in LPS-induced Human Primary Astrocytes</article-title><source>Int. J. Tryptophan Res.</source><year>2020</year><volume>13</volume><fpage>1178646920978404</fpage><pub-id pub-id-type="doi">10.1177/1178646920978404</pub-id><pub-id pub-id-type="pmid">33447046</pub-id><pub-id pub-id-type="pmcid">PMC7780186</pub-id></element-citation></ref><ref id="B42-molecules-30-03628"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>R.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mizoi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Okuma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hosokawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanzaki</surname><given-names>T.</given-names></name></person-group><article-title>Indole-3-propionic acid has chemical chaperone activity and suppresses endoplasmic reticulum stress-induced neuronal cell death</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2019</year><volume>517</volume><fpage>623</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.07.074</pub-id><pub-id pub-id-type="pmid">31378367</pub-id></element-citation></ref><ref id="B43-molecules-30-03628"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kumaran Satyanarayanan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Microbiota-derived metabolite Indoles induced aryl hydrocarbon receptor activation and inhibited neuroinflammation in APP/PS1 mice</article-title><source>Brain Behav. Immun.</source><year>2022</year><volume>106</volume><fpage>76</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2022.08.003</pub-id><pub-id pub-id-type="pmid">35961580</pub-id></element-citation></ref><ref id="B44-molecules-30-03628"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Synbiotic therapy with Clostridium sporogenes and xylan promotes gut-derived indole-3-propionic acid and improves cognitive impairments in an Alzheimer&#8217;s disease mouse model</article-title><source>Food Funct.</source><year>2024</year><volume>15</volume><fpage>7865</fpage><lpage>7882</lpage><pub-id pub-id-type="doi">10.1039/D4FO00886C</pub-id><pub-id pub-id-type="pmid">38967039</pub-id></element-citation></ref><ref id="B45-molecules-30-03628"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Dietary Methionine Restriction Alleviates Cognitive Impairment in Alzheimer&#8217;s Disease Mice via Sex-Dependent Modulation on Gut Microbiota and Tryptophan Metabolism: A Multiomics Analysis</article-title><source>J. Agric. Food Chem.</source><year>2025</year><volume>73</volume><fpage>1356</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.4c09878</pub-id><pub-id pub-id-type="pmid">39745486</pub-id></element-citation></ref><ref id="B46-molecules-30-03628"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fasina</surname><given-names>O.B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name></person-group><article-title>Tetradecyl 2,3-Dihydroxybenzoate Improves Cognitive Function in AD Mice by Modulating Autophagy and Inflammation Through IPA and Hsc70 Targeting</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>11719</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252111719</pub-id><pub-id pub-id-type="pmid">39519271</pub-id><pub-id pub-id-type="pmcid">PMC11547019</pub-id></element-citation></ref><ref id="B47-molecules-30-03628"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>855</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14676-4</pub-id><pub-id pub-id-type="pmid">32071312</pub-id><pub-id pub-id-type="pmcid">PMC7029019</pub-id></element-citation></ref><ref id="B48-molecules-30-03628"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Indole-3-propionic acid alleviates ischemic brain injury in a mouse middle cerebral artery occlusion model</article-title><source>Exp. Neurol.</source><year>2022</year><volume>353</volume><fpage>114081</fpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2022.114081</pub-id><pub-id pub-id-type="pmid">35405119</pub-id></element-citation></ref><ref id="B49-molecules-30-03628"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peesh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blasco-Conesa</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>El Hamamy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>Honarpisheh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohan</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Benefits of equilibrium between microbiota- and host-derived ligands of the aryl hydrocarbon receptor after stroke in aged male mice</article-title><source>Nat. Commun.</source><year>2025</year><volume>16</volume><fpage>1767</fpage><pub-id pub-id-type="doi">10.1038/s41467-025-57014-2</pub-id><pub-id pub-id-type="pmid">39971928</pub-id><pub-id pub-id-type="pmcid">PMC11839985</pub-id></element-citation></ref><ref id="B50-molecules-30-03628"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dagnew</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Hippocampal Neural Dynamics and Postoperative Delirium-like Behavior in Aged Mice</article-title><source>Anesthesiology</source><year>2025</year><volume>143</volume><fpage>625</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000005478</pub-id><pub-id pub-id-type="pmid">40153532</pub-id></element-citation></ref><ref id="B51-molecules-30-03628"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name></person-group><article-title>Protective effects of indole-3-propionic acid against TCP-induced hearing loss in mice by mitigating oxidative stress and promoting neutrophil recruitment</article-title><source>Sci. Rep.</source><year>2025</year><volume>15</volume><elocation-id>9434</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-025-90655-3</pub-id><pub-id pub-id-type="pmid">40108188</pub-id><pub-id pub-id-type="pmcid">PMC11923075</pub-id></element-citation></ref><ref id="B52-molecules-30-03628"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Microbiota-indole 3-propionic acid-brain axis mediates abnormal synaptic pruning of hippocampal microglia and susceptibility to ASD in IUGR offspring</article-title><source>Microbiome</source><year>2023</year><volume>11</volume><elocation-id>245</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-023-01656-1</pub-id><pub-id pub-id-type="pmid">37932832</pub-id><pub-id pub-id-type="pmcid">PMC10629055</pub-id></element-citation></ref><ref id="B53-molecules-30-03628"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The gut metabolite indole-3-propionic acid activates ERK1 to restore social function and hippocampal inhibitory synaptic transmission in a 16p11.2 microdeletion mouse model</article-title><source>Microbiome</source><year>2024</year><volume>12</volume><elocation-id>66</elocation-id><pub-id pub-id-type="doi">10.1186/s40168-024-01755-7</pub-id><pub-id pub-id-type="pmid">38549163</pub-id><pub-id pub-id-type="pmcid">PMC10976717</pub-id></element-citation></ref><ref id="B54-molecules-30-03628"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothhammer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mascanfroni</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Takenaka</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Kenison</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blain</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor</article-title><source>Nat. Med.</source><year>2016</year><volume>22</volume><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/nm.4106</pub-id><pub-id pub-id-type="pmid">27158906</pub-id><pub-id pub-id-type="pmcid">PMC4899206</pub-id></element-citation></ref><ref id="B55-molecules-30-03628"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owumi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Adebisi</surname><given-names>G.</given-names></name></person-group><article-title>Epirubicin Treatment Induces Neurobehavioral, Oxido-Inflammatory and Neurohistology Alterations in Rats: Protective Effect of the Endogenous Metabolite of Tryptophan -&#8201;3-Indolepropionic Acid</article-title><source>Neurochem. Res.</source><year>2023</year><volume>48</volume><fpage>2767</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1007/s11064-023-03941-9</pub-id><pub-id pub-id-type="pmid">37097396</pub-id></element-citation></ref><ref id="B56-molecules-30-03628"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luengo-Gutierrez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Crawford</surname><given-names>G.</given-names></name><name name-style="western"><surname>Danzi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Myridakis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brandis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bello</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>The gut metabolite indole-3 propionate promotes nerve regeneration and repair</article-title><source>Nature</source><year>2022</year><volume>607</volume><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04884-x</pub-id><pub-id pub-id-type="pmid">35732737</pub-id></element-citation></ref><ref id="B57-molecules-30-03628"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>UPLC-Q-TOF/MS-based plasma metabolome to identify biomarkers and time of injury in traumatic brain injured rats</article-title><source>Neuroreport</source><year>2021</year><volume>32</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1097/WNR.0000000000001576</pub-id><pub-id pub-id-type="pmid">33788810</pub-id></element-citation></ref><ref id="B58-molecules-30-03628"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.N.</given-names></name></person-group><article-title>Discovery of a Metabolic Signature Predisposing High Risk Patients with Mild Cognitive Impairment to Converting to Alzheimer&#8217;s Disease</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>10903</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222010903</pub-id><pub-id pub-id-type="pmid">34681563</pub-id><pub-id pub-id-type="pmcid">PMC8535253</pub-id></element-citation></ref><ref id="B59-molecules-30-03628"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Study on the correlation between serum indole-3-propionic acid levels and the progression and prognosis of acute ischemic stroke</article-title><source>J. Stroke Cerebrovasc. Dis.</source><year>2024</year><volume>33</volume><fpage>107680</fpage><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2024.107680</pub-id><pub-id pub-id-type="pmid">38508478</pub-id></element-citation></ref><ref id="B60-molecules-30-03628"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaetani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Boscaro</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pieraccini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Romani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Filippo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zelante</surname><given-names>T.</given-names></name></person-group><article-title>Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>157</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00157</pub-id><pub-id pub-id-type="pmid">32132996</pub-id><pub-id pub-id-type="pmcid">PMC7041364</pub-id></element-citation></ref><ref id="B61-molecules-30-03628"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Beau</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Carver</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Espinosa</surname><given-names>R.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Schmidt</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Bradfield</surname><given-names>C.A.</given-names></name></person-group><article-title>Chromosomal localization of the human AHR locus encoding the structural gene for the Ah receptor to 7p21 &#8594; p15</article-title><source>Cytogenet. Cell Genet.</source><year>1994</year><volume>66</volume><fpage>172</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1159/000133694</pub-id><pub-id pub-id-type="pmid">8125016</pub-id></element-citation></ref><ref id="B62-molecules-30-03628"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez-V&#225;zquez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>F.J.</given-names></name></person-group><article-title>Regulation of the Immune Response by the Aryl Hydrocarbon Receptor</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>19</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.12.012</pub-id><pub-id pub-id-type="pmid">29343438</pub-id><pub-id pub-id-type="pmcid">PMC5777317</pub-id></element-citation></ref><ref id="B63-molecules-30-03628"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barroso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahler</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Fonseca-Castro</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>F.J.</given-names></name></person-group><article-title>The aryl hydrocarbon receptor and the gut-brain axis</article-title><source>Cell Mol. Immunol.</source><year>2021</year><volume>18</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-00585-5</pub-id><pub-id pub-id-type="pmid">33408340</pub-id><pub-id pub-id-type="pmcid">PMC8027889</pub-id></element-citation></ref><ref id="B64-molecules-30-03628"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwaniak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Owe-Larsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urba&#324;ska</surname><given-names>E.M.</given-names></name></person-group><article-title>Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson&#8217;s Disease-A Narrative Review</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>2915</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25052915</pub-id><pub-id pub-id-type="pmid">38474162</pub-id><pub-id pub-id-type="pmcid">PMC10931713</pub-id></element-citation></ref><ref id="B65-molecules-30-03628"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name></person-group><article-title>Activation of aryl hydrocarbon receptor (AhR) in Alzheimer&#8217;s disease: Role of tryptophan metabolites generated by gut host-microbiota</article-title><source>J. Mol. Med.</source><year>2023</year><volume>101</volume><fpage>201</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1007/s00109-023-02289-5</pub-id><pub-id pub-id-type="pmid">36757399</pub-id><pub-id pub-id-type="pmcid">PMC10036442</pub-id></element-citation></ref><ref id="B66-molecules-30-03628"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sondermann</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Fa&#223;bender</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>F.</given-names></name><name name-style="western"><surname>H&#228;t&#228;l&#228;</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rolfes</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>C.F.A.</given-names></name><name name-style="western"><surname>Haarmann-Stemmann</surname><given-names>T.</given-names></name></person-group><article-title>Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway</article-title><source>Biochem. Pharmacol.</source><year>2023</year><volume>208</volume><elocation-id>115371</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2022.115371</pub-id><pub-id pub-id-type="pmid">36528068</pub-id><pub-id pub-id-type="pmcid">PMC9884176</pub-id></element-citation></ref><ref id="B67-molecules-30-03628"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockinger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Di Meglio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gialitakis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duarte</surname><given-names>J.H.</given-names></name></person-group><article-title>The aryl hydrocarbon receptor: Multitasking in the immune system</article-title><source>Annu. Rev. Immunol.</source><year>2014</year><volume>32</volume><fpage>403</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120245</pub-id><pub-id pub-id-type="pmid">24655296</pub-id></element-citation></ref><ref id="B68-molecules-30-03628"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothhammer</surname><given-names>V.</given-names></name><name name-style="western"><surname>Quintana</surname><given-names>F.J.</given-names></name></person-group><article-title>The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>184</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0125-8</pub-id><pub-id pub-id-type="pmid">30718831</pub-id></element-citation></ref><ref id="B69-molecules-30-03628"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farooqi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rakhmetova</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kapanova</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tanbayeva</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mussakhanova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abdykulova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ryskulova</surname><given-names>A.G.</given-names></name></person-group><article-title>Role of Ubiquitination and Epigenetics in the Regulation of AhR Signaling in Carcinogenesis and Metastasis: &#8220;Albatross around the Neck&#8221; or &#8220;Blessing in Disguise&#8221;</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>2382</elocation-id><pub-id pub-id-type="doi">10.3390/cells12192382</pub-id><pub-id pub-id-type="pmid">37830596</pub-id><pub-id pub-id-type="pmcid">PMC10571945</pub-id></element-citation></ref><ref id="B70-molecules-30-03628"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gargaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pallotta</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Matino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Servillo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Brunacci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bicciato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Macchiarulo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vacca</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Aryl hydrocarbon receptor control of a disease tolerance defence pathway</article-title><source>Nature</source><year>2014</year><volume>511</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nature13323</pub-id><pub-id pub-id-type="pmid">24930766</pub-id><pub-id pub-id-type="pmcid">PMC4098076</pub-id></element-citation></ref><ref id="B71-molecules-30-03628"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tohyama</surname><given-names>C.</given-names></name></person-group><article-title>Embryonic and Postnatal Expression of Aryl Hydrocarbon Receptor mRNA in Mouse Brain</article-title><source>Front. Neuroanat.</source><year>2017</year><volume>11</volume><elocation-id>4</elocation-id><pub-id pub-id-type="doi">10.3389/fnana.2017.00004</pub-id><pub-id pub-id-type="pmid">28223923</pub-id><pub-id pub-id-type="pmcid">PMC5293765</pub-id></element-citation></ref><ref id="B72-molecules-30-03628"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamas</surname><given-names>B.</given-names></name><name name-style="western"><surname>Natividad</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sokol</surname><given-names>H.</given-names></name></person-group><article-title>Aryl hydrocarbon receptor and intestinal immunity</article-title><source>Mucosal Immunol.</source><year>2018</year><volume>11</volume><fpage>1024</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0019-2</pub-id><pub-id pub-id-type="pmid">29626198</pub-id></element-citation></ref><ref id="B73-molecules-30-03628"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Z.B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.X.</given-names></name></person-group><article-title>Gut microbiota-derived indole 3-propionic acid partially activates aryl hydrocarbon receptor to promote macrophage phagocytosis and attenuate septic injury</article-title><source>Front. Cell Infect. Microbiol.</source><year>2022</year><volume>12</volume><elocation-id>1015386</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2022.1015386</pub-id><pub-id pub-id-type="pmid">36299625</pub-id><pub-id pub-id-type="pmcid">PMC9589056</pub-id></element-citation></ref><ref id="B74-molecules-30-03628"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name></person-group><article-title>Indole-3-propionic acid alleviates chondrocytes inflammation and osteoarthritis via the AhR/NF-&#954;B axis</article-title><source>Mol. Med.</source><year>2023</year><volume>29</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s10020-023-00614-9</pub-id><pub-id pub-id-type="pmid">36721094</pub-id><pub-id pub-id-type="pmcid">PMC9890697</pub-id></element-citation></ref><ref id="B75-molecules-30-03628"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venkatesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benechet</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Maher</surname><given-names>L.</given-names></name><name name-style="western"><surname>Redinbo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4</article-title><source>Immunity</source><year>2014</year><volume>41</volume><fpage>296</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.06.014</pub-id><pub-id pub-id-type="pmid">25065623</pub-id><pub-id pub-id-type="pmcid">PMC4142105</pub-id></element-citation></ref><ref id="B76-molecules-30-03628"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yisireyili</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Murohara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Niwa</surname><given-names>T.</given-names></name></person-group><article-title>Indole-3-propionic acid suppresses indoxyl sulfate-induced expression of fibrotic and inflammatory genes in proximal tubular cells</article-title><source>Nagoya J. Med. Sci.</source><year>2017</year><volume>79</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.18999/nagjms.79.4.477</pub-id><pub-id pub-id-type="pmid">29238104</pub-id><pub-id pub-id-type="pmcid">PMC5719207</pub-id></element-citation></ref><ref id="B77-molecules-30-03628"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrzalov&#225;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pe&#269;inkov&#225;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ill&#233;s</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gursk&#225;</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#382;ub&#225;k</surname><given-names>P.</given-names></name><name name-style="western"><surname>Szotkowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hajd&#250;ch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dvo&#345;&#225;k</surname><given-names>Z.</given-names></name></person-group><article-title>Mixture Effects of Tryptophan Intestinal Microbial Metabolites on Aryl Hydrocarbon Receptor Activity</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>10825</elocation-id><pub-id pub-id-type="doi">10.3390/ijms231810825</pub-id><pub-id pub-id-type="pmid">36142735</pub-id><pub-id pub-id-type="pmcid">PMC9505659</pub-id></element-citation></ref><ref id="B78-molecules-30-03628"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Armad</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.Y.</given-names></name></person-group><article-title>Maternal PBDE exposure disrupts gut microbiome and promotes hepatic proinflammatory signaling in humanized PXR-transgenic mouse offspring over time</article-title><source>Toxicol. Sci.</source><year>2023</year><volume>194</volume><fpage>209</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfad056</pub-id><pub-id pub-id-type="pmid">37267213</pub-id><pub-id pub-id-type="pmcid">PMC10375318</pub-id></element-citation></ref><ref id="B79-molecules-30-03628"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuehl</surname><given-names>P.</given-names></name><name name-style="western"><surname>Green</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Touchman</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Maurel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Relling</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brimer</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants</article-title><source>Pharmacogenet. Genom.</source><year>2001</year><volume>11</volume><fpage>555</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1097/00008571-200110000-00003</pub-id><pub-id pub-id-type="pmid">11668216</pub-id></element-citation></ref><ref id="B80-molecules-30-03628"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name></person-group><article-title>Role of nuclear receptor PXR in immune cells and inflammatory diseases</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>969399</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.969399</pub-id><pub-id pub-id-type="pmid">36119030</pub-id><pub-id pub-id-type="pmcid">PMC9481241</pub-id></element-citation></ref><ref id="B81-molecules-30-03628"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres-Vergara</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nualart</surname><given-names>F.</given-names></name><name name-style="western"><surname>Escudero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Penny</surname><given-names>J.</given-names></name></person-group><article-title>The constitutive androstane receptor and pregnane X receptor in the brain</article-title><source>Br. J. Pharmacol.</source><year>2020</year><volume>177</volume><fpage>2666</fpage><lpage>2682</lpage><pub-id pub-id-type="doi">10.1111/bph.15055</pub-id><pub-id pub-id-type="pmid">32201941</pub-id><pub-id pub-id-type="pmcid">PMC7236070</pub-id></element-citation></ref><ref id="B82-molecules-30-03628"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kliewer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Willson</surname><given-names>T.M.</given-names></name></person-group><article-title>The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism</article-title><source>Endocr. Rev.</source><year>2002</year><volume>23</volume><fpage>687</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1210/er.2001-0038</pub-id><pub-id pub-id-type="pmid">12372848</pub-id></element-citation></ref><ref id="B83-molecules-30-03628"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Mota</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>W.S.</given-names></name></person-group><article-title>Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation</article-title><source>Curr. Pharmacogenom. Person. Med.</source><year>2009</year><volume>7</volume><fpage>81</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.2174/187569209788654005</pub-id><pub-id pub-id-type="pmcid">PMC2944248</pub-id><pub-id pub-id-type="pmid">20871735</pub-id></element-citation></ref><ref id="B84-molecules-30-03628"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.Y.</given-names></name></person-group><article-title>Pregnane X Receptor and the Gut-Liver Axis: A Recent Update</article-title><source>Drug Metab. Dispos.</source><year>2022</year><volume>50</volume><fpage>478</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1124/dmd.121.000415</pub-id><pub-id pub-id-type="pmid">34862253</pub-id><pub-id pub-id-type="pmcid">PMC11022899</pub-id></element-citation></ref><ref id="B85-molecules-30-03628"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bautista-Olivier</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Elizondo</surname><given-names>G.</given-names></name></person-group><article-title>PXR as the tipping point between innate immune response, microbial infections, and drug metabolism</article-title><source>Biochem. Pharmacol.</source><year>2022</year><volume>202</volume><elocation-id>115147</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2022.115147</pub-id><pub-id pub-id-type="pmid">35714683</pub-id></element-citation></ref><ref id="B86-molecules-30-03628"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nieves</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Flannigan</surname><given-names>K.L.</given-names></name></person-group><article-title>Xenobiotic receptors and the regulation of intestinal homeostasis: Harnessing the chemical output of the intestinal microbiota</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2022</year><volume>322</volume><fpage>G268</fpage><lpage>G281</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00160.2021</pub-id><pub-id pub-id-type="pmid">34941453</pub-id></element-citation></ref><ref id="B87-molecules-30-03628"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frye</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Paris</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Walf</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rusconi</surname><given-names>J.C.</given-names></name></person-group><article-title>Effects and Mechanisms of 3&#945;,5&#945;,-THP on Emotion, Motivation, and Reward Functions Involving Pregnane Xenobiotic Receptor</article-title><source>Front. Neurosci.</source><year>2011</year><volume>5</volume><elocation-id>136</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2011.00136</pub-id><pub-id pub-id-type="pmid">22294977</pub-id><pub-id pub-id-type="pmcid">PMC3261425</pub-id></element-citation></ref><ref id="B88-molecules-30-03628"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbownik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lewi&#324;ski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name></person-group><article-title>Carcinogen-induced, free radical-mediated reduction in microsomal membrane fluidity: Reversal by indole-3-propionic acid</article-title><source>J. Bioenerg. Biomembr.</source><year>2001</year><volume>33</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1023/A:1005628808688</pub-id><pub-id pub-id-type="pmid">11460928</pub-id></element-citation></ref><ref id="B89-molecules-30-03628"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbownik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burkhardt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Osuna</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lewi&#324;ski</surname><given-names>A.</given-names></name></person-group><article-title>Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: Relevance to cancer reduction</article-title><source>J. Cell Biochem.</source><year>2001</year><volume>81</volume><fpage>507</fpage><lpage>513</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-4644(20010601)81:3&amp;#x0003c;507::AID-JCB1064&amp;#x0003e;3.0.CO;2-M</pub-id><pub-id pub-id-type="pmid">11255233</pub-id></element-citation></ref><ref id="B90-molecules-30-03628"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbownik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stasiak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zygmunt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zasada</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lewi&#324;ski</surname><given-names>A.</given-names></name></person-group><article-title>Protective effects of melatonin and indole-3-propionic acid against lipid peroxidation, caused by potassium bromate in the rat kidney</article-title><source>Cell Biochem. Funct.</source><year>2006</year><volume>24</volume><fpage>483</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1002/cbf.1321</pub-id><pub-id pub-id-type="pmid">16397908</pub-id></element-citation></ref><ref id="B91-molecules-30-03628"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sambamurti</surname><given-names>K.</given-names></name><name name-style="western"><surname>Siedlak</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>G.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name></person-group><article-title>A novel endogenous indole protects rodent mitochondria and extends rotifer lifespan</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e10206</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0010206</pub-id><pub-id pub-id-type="pmid">20421998</pub-id><pub-id pub-id-type="pmcid">PMC2858081</pub-id></element-citation></ref><ref id="B92-molecules-30-03628"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Manchester</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J.J.</given-names></name></person-group><article-title>Increased levels of oxidatively damaged DNA induced by chromium(III) and H<sub>2</sub>O<sub>2</sub>: Protection by melatonin and related molecules</article-title><source>J. Pineal Res.</source><year>2000</year><volume>29</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1034/j.1600-079X.2000.290108.x</pub-id><pub-id pub-id-type="pmid">10949541</pub-id></element-citation></ref><ref id="B93-molecules-30-03628"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karbownik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Cabrera</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>J.J.</given-names></name></person-group><article-title>Comparison of the protective effect of melatonin with other antioxidants in the hamster kidney model of estradiol-induced DNA damage</article-title><source>Mutat. Res.</source><year>2001</year><volume>474</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0027-5107(00)00164-0</pub-id><pub-id pub-id-type="pmid">11239965</pub-id></element-citation></ref><ref id="B94-molecules-30-03628"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morzyk-Ociepa</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rozycka-Sokolowska</surname><given-names>E.</given-names></name></person-group><article-title>X-ray and infrared spectrum on metal complexes with indolecarboxylic acids: Part, V. Catena-poly[{aqua(&#951;2-indole-3-propionato-O,O&#8242;)zinc}-&#951;2-:-&#956;-indole-3-propionato-O, O&#8242;:-O]</article-title><source>Vib. Spectrosc.</source><year>2007</year><volume>43</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1016/j.vibspec.2006.04.027</pub-id></element-citation></ref><ref id="B95-molecules-30-03628"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owumi</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Adedara</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Oyelere</surname><given-names>A.K.</given-names></name></person-group><article-title>Indole-3-propionic acid mitigates chlorpyrifos-mediated neurotoxicity by modulating cholinergic and redox-regulatory systems, inflammatory stress, apoptotic responses and DNA damage in rats</article-title><source>Environ. Toxicol. Pharmacol.</source><year>2022</year><volume>89</volume><fpage>103786</fpage><pub-id pub-id-type="doi">10.1016/j.etap.2021.103786</pub-id><pub-id pub-id-type="pmid">34915193</pub-id></element-citation></ref><ref id="B96-molecules-30-03628"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sch&#252;tz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Krause</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Taudte</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Zaiss</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Luu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Visekruna</surname><given-names>A.</given-names></name></person-group><article-title>Modulation of Host Immunity by Microbiome-Derived Indole-3-Propionic Acid and Other Bacterial Metabolites</article-title><source>Eur. J. Immunol.</source><year>2025</year><volume>55</volume><fpage>e202451594</fpage><pub-id pub-id-type="doi">10.1002/eji.202451594</pub-id><pub-id pub-id-type="pmid">40170399</pub-id><pub-id pub-id-type="pmcid">PMC11962249</pub-id></element-citation></ref><ref id="B97-molecules-30-03628"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>An</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name></person-group><article-title>The mechanism of action of indole-3-propionic acid on bone metabolism</article-title><source>Food Funct.</source><year>2025</year><volume>16</volume><fpage>406</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1039/D4FO03783A</pub-id><pub-id pub-id-type="pmid">39764708</pub-id></element-citation></ref><ref id="B98-molecules-30-03628"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paeslack</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mimmler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khuu</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Malinarich</surname><given-names>F.</given-names></name><name name-style="western"><surname>Regen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Reinhardt</surname><given-names>C.</given-names></name></person-group><article-title>Microbiota-derived tryptophan metabolites in vascular inflammation and cardiovascular disease</article-title><source>Amino Acids</source><year>2022</year><volume>54</volume><fpage>1339</fpage><lpage>1356</lpage><pub-id pub-id-type="doi">10.1007/s00726-022-03161-5</pub-id><pub-id pub-id-type="pmid">35451695</pub-id><pub-id pub-id-type="pmcid">PMC9641817</pub-id></element-citation></ref><ref id="B99-molecules-30-03628"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teunis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nieuwdorp</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanssen</surname><given-names>N.</given-names></name></person-group><article-title>Interactions between Tryptophan Metabolism, the Gut Microbiome and the Immune System as Potential Drivers of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Diseases</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><elocation-id>514</elocation-id><pub-id pub-id-type="doi">10.3390/metabo12060514</pub-id><pub-id pub-id-type="pmid">35736447</pub-id><pub-id pub-id-type="pmcid">PMC9227929</pub-id></element-citation></ref><ref id="B100-molecules-30-03628"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name></person-group><article-title>Indolepropionic acid modulates the immune response in allergic rhinitis through the AKT/CEBPB/IL-10 signaling pathway</article-title><source>Mol. Med. Rep.</source><year>2025</year><volume>32</volume><fpage>204</fpage><pub-id pub-id-type="doi">10.3892/mmr.2025.13569</pub-id><pub-id pub-id-type="pmid">40417918</pub-id><pub-id pub-id-type="pmcid">PMC12117527</pub-id></element-citation></ref><ref id="B101-molecules-30-03628"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabarathinam</surname><given-names>S.</given-names></name></person-group><article-title>Deciphering the gut microbiota&#8217;s (Coprococcus and Subdoligranulum) impact on depression: Network pharmacology and molecular dynamics simulation</article-title><source>Pharmacol. Biochem. Behav.</source><year>2024</year><volume>241</volume><elocation-id>173805</elocation-id><pub-id pub-id-type="doi">10.1016/j.pbb.2024.173805</pub-id><pub-id pub-id-type="pmid">38848976</pub-id></element-citation></ref><ref id="B102-molecules-30-03628"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Gut Metabolite Indole-3-Propionic Acid Regulates Macrophage Autophagy Through PPT1 Inhibiting Aging-Related Myocardial Fibrosis</article-title><source>Adv. Sci.</source><year>2025</year><fpage>e01070</fpage><pub-id pub-id-type="doi">10.1002/advs.202501070</pub-id><pub-id pub-id-type="pmid">40539882</pub-id></element-citation></ref><ref id="B103-molecules-30-03628"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savitz</surname><given-names>J.</given-names></name></person-group><article-title>The kynurenine pathway: A finger in every pie</article-title><source>Mol. Psychiatry</source><year>2020</year><volume>25</volume><fpage>131</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1038/s41380-019-0414-4</pub-id><pub-id pub-id-type="pmid">30980044</pub-id><pub-id pub-id-type="pmcid">PMC6790159</pub-id></element-citation></ref><ref id="B104-molecules-30-03628"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badawy</surname><given-names>A.A.</given-names></name></person-group><article-title>Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects</article-title><source>Int. J. Tryptophan Res.</source><year>2017</year><volume>10</volume><fpage>1178646917691938</fpage><pub-id pub-id-type="doi">10.1177/1178646917691938</pub-id><pub-id pub-id-type="pmid">28469468</pub-id><pub-id pub-id-type="pmcid">PMC5398323</pub-id></element-citation></ref><ref id="B105-molecules-30-03628"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stone</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Darlington</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Badawy</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.O.</given-names></name></person-group><article-title>The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>9040</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25169040</pub-id><pub-id pub-id-type="pmid">39201726</pub-id><pub-id pub-id-type="pmcid">PMC11354734</pub-id></element-citation></ref><ref id="B106-molecules-30-03628"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Somarribas Patterson</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>&#214;zt&#252;rk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Panitz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Secker</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Pf&#228;nder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Loth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>H.</given-names></name><name name-style="western"><surname>Prentzell</surname><given-names>M.T.</given-names></name><etal/></person-group><article-title>IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>1252</fpage><lpage>1270.E34</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.038</pub-id><pub-id pub-id-type="pmid">32818467</pub-id></element-citation></ref><ref id="B107-molecules-30-03628"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>G&#252;ner</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Iradukunda</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>J.P.</given-names></name></person-group><article-title>The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>273</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27010273</pub-id><pub-id pub-id-type="pmid">35011505</pub-id><pub-id pub-id-type="pmcid">PMC8747024</pub-id></element-citation></ref><ref id="B108-molecules-30-03628"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciapa&#322;a</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mika</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rojewska</surname><given-names>E.</given-names></name></person-group><article-title>The Kynurenine Pathway as a Potential Target for Neuropathic Pain Therapy Design: From Basic Research to Clinical Perspectives</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>11055</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222011055</pub-id><pub-id pub-id-type="pmid">34681715</pub-id><pub-id pub-id-type="pmcid">PMC8537209</pub-id></element-citation></ref><ref id="B109-molecules-30-03628"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Szab&#243;</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>V&#233;csei</surname><given-names>L.</given-names></name></person-group><article-title>Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>12767</elocation-id><pub-id pub-id-type="doi">10.3390/ijms252312767</pub-id><pub-id pub-id-type="pmid">39684480</pub-id><pub-id pub-id-type="pmcid">PMC11640972</pub-id></element-citation></ref><ref id="B110-molecules-30-03628"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pocivavsek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schwarcz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Erhardt</surname><given-names>S.</given-names></name></person-group><article-title>Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities</article-title><source>Pharmacol. Rev.</source><year>2024</year><volume>76</volume><fpage>978</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1124/pharmrev.124.000239</pub-id><pub-id pub-id-type="pmid">39304346</pub-id><pub-id pub-id-type="pmcid">PMC11549936</pub-id></element-citation></ref><ref id="B111-molecules-30-03628"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tankiewicz-Kwedlo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciwun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lewkowicz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pawlak</surname><given-names>D.</given-names></name></person-group><article-title>Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders</article-title><source>Cells</source><year>2024</year><volume>13</volume><elocation-id>1259</elocation-id><pub-id pub-id-type="doi">10.3390/cells13151259</pub-id><pub-id pub-id-type="pmid">39120289</pub-id><pub-id pub-id-type="pmcid">PMC11311768</pub-id></element-citation></ref><ref id="B112-molecules-30-03628"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozie&#322;</surname><given-names>K.</given-names></name><name name-style="western"><surname>Urbanska</surname><given-names>E.M.</given-names></name></person-group><article-title>Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target?</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>460</elocation-id><pub-id pub-id-type="doi">10.3390/cells12030460</pub-id><pub-id pub-id-type="pmid">36766803</pub-id><pub-id pub-id-type="pmcid">PMC9913876</pub-id></element-citation></ref><ref id="B113-molecules-30-03628"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Owe-Larsson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urbanska</surname><given-names>E.M.</given-names></name></person-group><article-title>New Perspective on Anorexia Nervosa: Tryptophan-Kynurenine Pathway Hypothesis</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>1030</elocation-id><pub-id pub-id-type="doi">10.3390/nu15041030</pub-id><pub-id pub-id-type="pmid">36839388</pub-id><pub-id pub-id-type="pmcid">PMC9967350</pub-id></element-citation></ref><ref id="B114-molecules-30-03628"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorgdrager</surname><given-names>F.J.H.</given-names></name><name name-style="western"><surname>Naud&#233;</surname><given-names>P.J.W.</given-names></name><name name-style="western"><surname>Kema</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Nollen</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Deyn</surname><given-names>P.P.</given-names></name></person-group><article-title>Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>2565</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02565</pub-id><pub-id pub-id-type="pmid">31736978</pub-id><pub-id pub-id-type="pmcid">PMC6833926</pub-id></element-citation></ref><ref id="B115-molecules-30-03628"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name></person-group><article-title>Kynurenine Pathway Metabolites as Biomarkers in Alzheimer&#8217;s Disease</article-title><source>Dis. Markers</source><year>2022</year><volume>2022</volume><fpage>9484217</fpage><pub-id pub-id-type="doi">10.1155/2022/9484217</pub-id><pub-id pub-id-type="pmid">35096208</pub-id><pub-id pub-id-type="pmcid">PMC8791723</pub-id></element-citation></ref><ref id="B116-molecules-30-03628"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urenjak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Obrenovitch</surname><given-names>T.P.</given-names></name></person-group><article-title>Neuroprotective potency of kynurenic acid against excitotoxicity</article-title><source>Neuroreport</source><year>2000</year><volume>11</volume><fpage>1341</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1097/00001756-200004270-00038</pub-id><pub-id pub-id-type="pmid">10817618</pub-id></element-citation></ref><ref id="B117-molecules-30-03628"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Kell</surname><given-names>D.B.</given-names></name></person-group><article-title>The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects</article-title><source>Int. J. Mol. Sci.</source><year>2024</year><volume>25</volume><elocation-id>9082</elocation-id><pub-id pub-id-type="doi">10.3390/ijms25169082</pub-id><pub-id pub-id-type="pmid">39201768</pub-id><pub-id pub-id-type="pmcid">PMC11354673</pub-id></element-citation></ref><ref id="B118-molecules-30-03628"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>F.C.</given-names></name></person-group><article-title>Therapeutic Potential of Nutritional Aryl Hydrocarbon Receptor Ligands in Gut-Related Inflammation and Diseases</article-title><source>Biomedicines</source><year>2024</year><volume>12</volume><elocation-id>2912</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines12122912</pub-id><pub-id pub-id-type="pmid">39767818</pub-id><pub-id pub-id-type="pmcid">PMC11673835</pub-id></element-citation></ref><ref id="B119-molecules-30-03628"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahman</surname><given-names>F.</given-names></name><name name-style="western"><surname>Choudhry</surname><given-names>K.</given-names></name><name name-style="western"><surname>Al-Rashed</surname><given-names>F.</given-names></name><name name-style="western"><surname>Al-Mulla</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sindhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>R.</given-names></name></person-group><article-title>Aryl hydrocarbon receptor: Current perspectives on key signaling partners and immunoregulatory role in inflammatory diseases</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1421346</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1421346</pub-id><pub-id pub-id-type="pmid">39211042</pub-id><pub-id pub-id-type="pmcid">PMC11358079</pub-id></element-citation></ref><ref id="B120-molecules-30-03628"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sathyasaikumar</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>P&#233;rez de la Cruz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pineda</surname><given-names>B.</given-names></name><name name-style="western"><surname>V&#225;zquez Cervantes</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Ram&#237;rez Ortega</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donley</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Severson</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>West</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Giorgini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Cellular Localization of Kynurenine 3-Monooxygenase in the Brain: Challenging the Dogma</article-title><source>Antioxidants</source><year>2022</year><volume>11</volume><elocation-id>315</elocation-id><pub-id pub-id-type="doi">10.3390/antiox11020315</pub-id><pub-id pub-id-type="pmid">35204197</pub-id><pub-id pub-id-type="pmcid">PMC8868204</pub-id></element-citation></ref><ref id="B121-molecules-30-03628"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwarcz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rapoport</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Takada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>Q.R.</given-names></name></person-group><article-title>Blood-brain barrier transport of kynurenines: Implications for brain synthesis and metabolism</article-title><source>J. Neurochem.</source><year>1991</year><volume>56</volume><fpage>2007</fpage><lpage>2017</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb03460.x</pub-id><pub-id pub-id-type="pmid">1827495</pub-id></element-citation></ref><ref id="B122-molecules-30-03628"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostapiuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Urbanska</surname><given-names>E.M.</given-names></name></person-group><article-title>Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?</article-title><source>CNS Neurosci. Ther.</source><year>2022</year><volume>28</volume><fpage>19</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1111/cns.13768</pub-id><pub-id pub-id-type="pmid">34862742</pub-id><pub-id pub-id-type="pmcid">PMC8673711</pub-id></element-citation></ref><ref id="B123-molecules-30-03628"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamptey</surname><given-names>R.N.L.</given-names></name><name name-style="western"><surname>Chaulagain</surname><given-names>B.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gothwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Layek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name></person-group><article-title>A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>1851</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031851</pub-id><pub-id pub-id-type="pmid">35163773</pub-id><pub-id pub-id-type="pmcid">PMC8837071</pub-id></element-citation></ref><ref id="B124-molecules-30-03628"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freisem</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoenigsperger</surname><given-names>H.</given-names></name><name name-style="western"><surname>Catanese</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sparrer</surname><given-names>K.M.J.</given-names></name></person-group><article-title>Inborn errors of canonical autophagy in neurodegenerative diseases</article-title><source>Hum. Mol. Genet.</source><year>2025</year><fpage>ddae179</fpage><pub-id pub-id-type="doi">10.1093/hmg/ddae179</pub-id><pub-id pub-id-type="pmid">40304712</pub-id></element-citation></ref><ref id="B125-molecules-30-03628"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dugger</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>D.W.</given-names></name></person-group><article-title>Pathology of Neurodegenerative Diseases</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2017</year><volume>9</volume><elocation-id>a028035</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a028035</pub-id><pub-id pub-id-type="pmid">28062563</pub-id><pub-id pub-id-type="pmcid">PMC5495060</pub-id></element-citation></ref><ref id="B126-molecules-30-03628"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argueti-Ostrovsky</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alfahel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Israelson</surname><given-names>A.</given-names></name></person-group><article-title>All Roads Lead to Rome: Different Molecular Players Converge to Common Toxic Pathways in Neurodegeneration</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>2438</elocation-id><pub-id pub-id-type="doi">10.3390/cells10092438</pub-id><pub-id pub-id-type="pmid">34572087</pub-id><pub-id pub-id-type="pmcid">PMC8468417</pub-id></element-citation></ref><ref id="B127-molecules-30-03628"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godoy</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Rios</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pic&#243;n-Pag&#232;s</surname><given-names>P.</given-names></name><name name-style="western"><surname>Herrera-Fern&#225;ndez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Swaby</surname><given-names>B.</given-names></name><name name-style="western"><surname>Crepin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Fern&#225;ndez</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>F.J.</given-names></name></person-group><article-title>Mitostasis, Calcium and Free Radicals in Health, Aging and Neurodegeneration</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>1012</elocation-id><pub-id pub-id-type="doi">10.3390/biom11071012</pub-id><pub-id pub-id-type="pmid">34356637</pub-id><pub-id pub-id-type="pmcid">PMC8301949</pub-id></element-citation></ref><ref id="B128-molecules-30-03628"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Trisal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name></person-group><article-title>Unlocking the therapeutic potential of gut microbiota for preventing and treating aging-related neurological disorders</article-title><source>Neuroscience</source><year>2025</year><volume>572</volume><fpage>190</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2025.03.020</pub-id><pub-id pub-id-type="pmid">40073931</pub-id></element-citation></ref><ref id="B129-molecules-30-03628"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name></person-group><article-title>Gut-brain axis and neurodegeneration: Mechanisms and therapeutic potentials</article-title><source>Front. Neurosci.</source><year>2024</year><volume>18</volume><elocation-id>1481390</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2024.1481390</pub-id><pub-id pub-id-type="pmid">39513042</pub-id><pub-id pub-id-type="pmcid">PMC11541110</pub-id></element-citation></ref><ref id="B130-molecules-30-03628"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morshedi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rezaei-Ghaleh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ebrahim-Habibi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmadian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemat-Gorgani</surname><given-names>M.</given-names></name></person-group><article-title>Inhibition of amyloid fibrillation of lysozyme by indole derivatives--possible mechanism of action</article-title><source>FEBS J.</source><year>2007</year><volume>274</volume><fpage>6415</fpage><lpage>6425</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.06158.x</pub-id><pub-id pub-id-type="pmid">18028426</pub-id></element-citation></ref><ref id="B131-molecules-30-03628"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>R.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name></person-group><article-title>Indole-3-Propionic Acid Attenuates Neuroinflammation and Cognitive Deficits by Inhibiting the RAGE-JAK2-STAT3 Signaling Pathway</article-title><source>J. Agric. Food Chem.</source><year>2025</year><volume>73</volume><fpage>5208</fpage><lpage>5222</lpage><pub-id pub-id-type="doi">10.1021/acs.jafc.4c08548</pub-id><pub-id pub-id-type="pmid">39992888</pub-id></element-citation></ref><ref id="B132-molecules-30-03628"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>K.</given-names></name></person-group><article-title>AGE-RAGE stress: A changing landscape in pathology and treatment of Alzheimer&#8217;s disease</article-title><source>Mol. Cell Biochem.</source><year>2019</year><volume>459</volume><fpage>95</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1007/s11010-019-03553-4</pub-id><pub-id pub-id-type="pmid">31079281</pub-id></element-citation></ref><ref id="B133-molecules-30-03628"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name></person-group><article-title>FPS-ZM1 inhibits LPS-induced microglial inflammation by suppressing JAK/STAT signaling pathway</article-title><source>Int. Immunopharmacol.</source><year>2021</year><volume>100</volume><fpage>108117</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2021.108117</pub-id><pub-id pub-id-type="pmid">34509933</pub-id></element-citation></ref><ref id="B134-molecules-30-03628"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P.</given-names></name><name name-style="western"><surname>De Strooper</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kivipelto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Holstege</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ch&#233;telat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Teunissen</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Flier</surname><given-names>W.M.</given-names></name></person-group><article-title>Alzheimer&#8217;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)32205-4</pub-id><pub-id pub-id-type="pmid">33667416</pub-id><pub-id pub-id-type="pmcid">PMC8354300</pub-id></element-citation></ref><ref id="B135-molecules-30-03628"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rostagno</surname><given-names>A.A.</given-names></name></person-group><article-title>Pathogenesis of Alzheimer&#8217;s Disease</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>24</volume><elocation-id>107</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24010107</pub-id><pub-id pub-id-type="pmid">36613544</pub-id><pub-id pub-id-type="pmcid">PMC9820480</pub-id></element-citation></ref><ref id="B136-molecules-30-03628"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#8217;Alessandro</surname><given-names>M.C.B.</given-names></name><name name-style="western"><surname>Kanaan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pratic&#242;</surname><given-names>D.</given-names></name><name name-style="western"><surname>Daher</surname><given-names>J.P.L.</given-names></name></person-group><article-title>Mitochondrial dysfunction in Alzheimer&#8217;s disease</article-title><source>Ageing Res. Rev.</source><year>2025</year><volume>107</volume><fpage>102713</fpage><pub-id pub-id-type="doi">10.1016/j.arr.2025.102713</pub-id><pub-id pub-id-type="pmid">40023293</pub-id></element-citation></ref><ref id="B137-molecules-30-03628"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Imbimbo</surname><given-names>B.P.</given-names></name></person-group><article-title>Are lecanemab and donanemab disease-modifying therapies?</article-title><source>Alzheimers Dement.</source><year>2024</year><volume>20</volume><fpage>6659</fpage><lpage>6661</lpage><pub-id pub-id-type="doi">10.1002/alz.14114</pub-id><pub-id pub-id-type="pmid">39096161</pub-id><pub-id pub-id-type="pmcid">PMC11497653</pub-id></element-citation></ref><ref id="B138-molecules-30-03628"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dragicevic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Copes</surname><given-names>N.</given-names></name><name name-style="western"><surname>O&#8217;Neal-Moffitt</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buzzeo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mamcarz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Olcese</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Arendash</surname><given-names>G.W.</given-names></name><etal/></person-group><article-title>Melatonin treatment restores mitochondrial function in Alzheimer&#8217;s mice: A mitochondrial protective role of melatonin membrane receptor signaling</article-title><source>J. Pineal Res.</source><year>2011</year><volume>51</volume><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1111/j.1600-079X.2011.00864.x</pub-id><pub-id pub-id-type="pmid">21355879</pub-id></element-citation></ref><ref id="B139-molecules-30-03628"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loganathan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kandasamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sakayanathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ameen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Iruthayaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thayumanavan</surname><given-names>P.</given-names></name></person-group><article-title>Amalgamation of experimental strategies, computational simulation, and computer-assisted-theoretical analysis to decipher the interaction of newly synthesized plumbagin-indole-3-propionic ester with cholinesterases</article-title><source>J. Biomol. Struct. Dyn.</source><year>2025</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1080/07391102.2025.2490058</pub-id><pub-id pub-id-type="pmid">40235310</pub-id></element-citation></ref><ref id="B140-molecules-30-03628"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sidhambaram</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sakayanathan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Loganathan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Iruthayaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thayumanavan</surname><given-names>P.</given-names></name></person-group><article-title>Esterified Indole-3-propionic Acid: A Novel Inhibitor against Cholinesterase Identified through Experimental and Computational Approaches</article-title><source>ACS Omega</source><year>2025</year><volume>10</volume><fpage>9073</fpage><lpage>9087</lpage><pub-id pub-id-type="doi">10.1021/acsomega.4c08149</pub-id><pub-id pub-id-type="pmid">40092751</pub-id><pub-id pub-id-type="pmcid">PMC11904713</pub-id></element-citation></ref><ref id="B141-molecules-30-03628"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bendheim</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Neria</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ziv</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chain</surname><given-names>D.G.</given-names></name></person-group><article-title>Development of indole-3-propionic acid (OXIGON) for Alzheimer&#8217;s disease</article-title><source>J. Mol. Neurosci.</source><year>2002</year><volume>19</volume><fpage>213</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/s12031-002-0036-0</pub-id><pub-id pub-id-type="pmid">12212784</pub-id></element-citation></ref><ref id="B142-molecules-30-03628"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Miravalle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zagorski</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Wisniewski</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chyan</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bryant-Thomas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frangione</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>14995</fpage><lpage>15001</lpage><pub-id pub-id-type="doi">10.1021/bi0114269</pub-id><pub-id pub-id-type="pmid">11732920</pub-id></element-citation></ref><ref id="B143-molecules-30-03628"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappolla</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Matsubara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pacheco-Quinto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poeggeler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zagorski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sambamurti</surname><given-names>K.</given-names></name></person-group><article-title>Melatonin Treatment Enhances A&#946; Lymphatic Clearance in a Transgenic Mouse Model of Amyloidosis</article-title><source>Curr. Alzheimer Res.</source><year>2018</year><volume>15</volume><fpage>637</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.2174/1567205015666180411092551</pub-id><pub-id pub-id-type="pmid">29637859</pub-id><pub-id pub-id-type="pmcid">PMC8803126</pub-id></element-citation></ref><ref id="B144-molecules-30-03628"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rynkowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>St&#281;pniak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karbownik-Lewi&#324;ska</surname><given-names>M.</given-names></name></person-group><article-title>Melatonin and Indole-3-Propionic Acid Reduce Oxidative Damage to Membrane Lipids Induced by High Iron Concentrations in Porcine Skin</article-title><source>Membranes</source><year>2021</year><volume>11</volume><elocation-id>571</elocation-id><pub-id pub-id-type="doi">10.3390/membranes11080571</pub-id><pub-id pub-id-type="pmid">34436334</pub-id><pub-id pub-id-type="pmcid">PMC8400501</pub-id></element-citation></ref><ref id="B145-molecules-30-03628"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stepniak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Karbownik-Lewinska</surname><given-names>M.</given-names></name></person-group><article-title>Cumulative Protective Effect of Melatonin and Indole-3-Propionic Acid against KIO<sub>3</sub>-Induced Lipid Peroxidation in Porcine Thyroid</article-title><source>Toxics</source><year>2021</year><volume>9</volume><elocation-id>89</elocation-id><pub-id pub-id-type="doi">10.3390/toxics9050089</pub-id><pub-id pub-id-type="pmid">33919052</pub-id><pub-id pub-id-type="pmcid">PMC8143077</pub-id></element-citation></ref><ref id="B146-molecules-30-03628"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tysnes</surname><given-names>O.B.</given-names></name><name name-style="western"><surname>Storstein</surname><given-names>A.</given-names></name></person-group><article-title>Epidemiology of Parkinson&#8217;s disease</article-title><source>J. Neural Transm.</source><year>2017</year><volume>124</volume><fpage>901</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1007/s00702-017-1686-y</pub-id><pub-id pub-id-type="pmid">28150045</pub-id></element-citation></ref><ref id="B147-molecules-30-03628"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volpicelli-Daley</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Luk</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Tanik</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Riddle</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Stieber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meaney</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Trojanowski</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V.M.</given-names></name></person-group><article-title>Exogenous &#945;-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death</article-title><source>Neuron</source><year>2011</year><volume>72</volume><fpage>57</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2011.08.033</pub-id><pub-id pub-id-type="pmid">21982369</pub-id><pub-id pub-id-type="pmcid">PMC3204802</pub-id></element-citation></ref><ref id="B148-molecules-30-03628"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riederer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nagatsu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Youdim</surname><given-names>M.B.H.</given-names></name><name name-style="western"><surname>Wulf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sian-Huelsmann</surname><given-names>J.</given-names></name></person-group><article-title>Lewy bodies, iron, inflammation and neuromelanin: Pathological aspects underlying Parkinson&#8217;s disease</article-title><source>J. Neural Transm.</source><year>2023</year><volume>130</volume><fpage>627</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1007/s00702-023-02630-9</pub-id><pub-id pub-id-type="pmid">37062012</pub-id><pub-id pub-id-type="pmcid">PMC10121516</pub-id></element-citation></ref><ref id="B149-molecules-30-03628"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name></person-group><article-title>Role of iron in brain development, aging, and neurodegenerative diseases</article-title><source>Ann. Med.</source><year>2025</year><volume>57</volume><fpage>2472871</fpage><pub-id pub-id-type="doi">10.1080/07853890.2025.2472871</pub-id><pub-id pub-id-type="pmid">40038870</pub-id><pub-id pub-id-type="pmcid">PMC11884104</pub-id></element-citation></ref><ref id="B150-molecules-30-03628"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramaniam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chesselet</surname><given-names>M.F.</given-names></name></person-group><article-title>Mitochondrial dysfunction and oxidative stress in Parkinson&#8217;s disease</article-title><source>Prog. Neurobiol.</source><year>2013</year><volume>106&#8211;107</volume><fpage>17</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.04.004</pub-id><pub-id pub-id-type="pmcid">PMC3742021</pub-id><pub-id pub-id-type="pmid">23643800</pub-id></element-citation></ref><ref id="B151-molecules-30-03628"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Brundin</surname><given-names>P.</given-names></name></person-group><article-title>Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology</article-title><source>Clin. Geriatr. Med.</source><year>2020</year><volume>36</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.cger.2019.08.002</pub-id><pub-id pub-id-type="pmid">31733690</pub-id><pub-id pub-id-type="pmcid">PMC6905381</pub-id></element-citation></ref><ref id="B152-molecules-30-03628"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wittung-Stafshede</surname><given-names>P.</given-names></name></person-group><article-title>Amyloids of &#945;-Synuclein Promote Chemical Transformations of Neuronal Cell Metabolites</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>12849</elocation-id><pub-id pub-id-type="doi">10.3390/ijms241612849</pub-id><pub-id pub-id-type="pmid">37629028</pub-id><pub-id pub-id-type="pmcid">PMC10454467</pub-id></element-citation></ref><ref id="B153-molecules-30-03628"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armstrong</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>M.S.</given-names></name></person-group><article-title>Diagnosis and Treatment of Parkinson Disease: A Review</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>548</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1001/jama.2019.22360</pub-id><pub-id pub-id-type="pmid">32044947</pub-id></element-citation></ref><ref id="B154-molecules-30-03628"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Z.</given-names></name></person-group><article-title>Gut Microbiota: A Novel Therapeutic Target for Parkinson&#8217;s Disease</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>937555</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.937555</pub-id><pub-id pub-id-type="pmid">35812394</pub-id><pub-id pub-id-type="pmcid">PMC9263276</pub-id></element-citation></ref><ref id="B155-molecules-30-03628"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Gut Flora Mediates the Rapid Tolerance of Electroacupuncture on Ischemic Stroke by Activating Melatonin Receptor through Regulating Indole-3-Propionic Acid</article-title><source>Am. J. Chin. Med.</source><year>2022</year><volume>50</volume><fpage>979</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1142/S0192415X22500409</pub-id><pub-id pub-id-type="pmid">35475976</pub-id></element-citation></ref><ref id="B156-molecules-30-03628"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangalam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poisson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nemutlu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>I.</given-names></name><name name-style="western"><surname>Denic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dzeja</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rattan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Giri</surname><given-names>S.</given-names></name></person-group><article-title>Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics</article-title><source>J. Clin. Cell Immunol.</source><year>2013</year><volume>4</volume><fpage>1000150</fpage><pub-id pub-id-type="doi">10.4172/2155-9899.1000150</pub-id><pub-id pub-id-type="pmcid">PMC3837296</pub-id><pub-id pub-id-type="pmid">24273690</pub-id></element-citation></ref><ref id="B157-molecules-30-03628"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Candeias</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Folkes</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Porssa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parrick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wardman</surname><given-names>P.</given-names></name></person-group><article-title>Enhancement of lipid peroxidation by indole-3-acetic acid and derivatives: Substituent effects</article-title><source>Free Radic. Res.</source><year>1995</year><volume>23</volume><fpage>403</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.3109/10715769509065262</pub-id><pub-id pub-id-type="pmid">7581824</pub-id></element-citation></ref><ref id="B158-molecules-30-03628"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haupt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keminer</surname><given-names>O.</given-names></name><name name-style="western"><surname>Neser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Windsh&#252;gel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wiltzsch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Pliushcheuskaya</surname><given-names>P.</given-names></name><name name-style="western"><surname>K&#252;nze</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>U.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing</article-title><source>Biochem. Pharmacol.</source><year>2025</year><volume>240</volume><elocation-id>117066</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2025.117066</pub-id><pub-id pub-id-type="pmid">40571216</pub-id></element-citation></ref><ref id="B159-molecules-30-03628"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janiga-MacNelly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vrazel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roat</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Fernandez-Luna</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Lavado</surname><given-names>R.</given-names></name></person-group><article-title>Exploring the biological impact of bacteria-derived indole compounds on human cell health: Cytotoxicity and cell proliferation across six cell lines</article-title><source>Toxicol. Rep.</source><year>2025</year><volume>14</volume><fpage>101883</fpage><pub-id pub-id-type="doi">10.1016/j.toxrep.2024.101883</pub-id><pub-id pub-id-type="pmid">39844884</pub-id><pub-id pub-id-type="pmcid">PMC11750580</pub-id></element-citation></ref><ref id="B160-molecules-30-03628"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name></person-group><article-title>Elucidating the Interaction of Indole-3-Propionic Acid and Calf Thymus DNA: Multispectroscopic and Computational Modeling Approaches</article-title><source>Foods</source><year>2024</year><volume>13</volume><elocation-id>1878</elocation-id><pub-id pub-id-type="doi">10.3390/foods13121878</pub-id><pub-id pub-id-type="pmid">38928819</pub-id><pub-id pub-id-type="pmcid">PMC11202999</pub-id></element-citation></ref><ref id="B161-molecules-30-03628"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salminen</surname><given-names>A.</given-names></name></person-group><article-title>Aryl hydrocarbon receptor (AhR) reveals evidence of antagonistic pleiotropy in the regulation of the aging process</article-title><source>Cell Mol. Life Sci.</source><year>2022</year><volume>79</volume><fpage>489</fpage><pub-id pub-id-type="doi">10.1007/s00018-022-04520-x</pub-id><pub-id pub-id-type="pmid">35987825</pub-id><pub-id pub-id-type="pmcid">PMC9392714</pub-id></element-citation></ref><ref id="B162-molecules-30-03628"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>G.Z.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Whiley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Hejndorf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.Z.</given-names></name><name name-style="western"><surname>Low</surname><given-names>J.Z.Y.</given-names></name><name name-style="western"><surname>Rossant</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tryptophan-metabolizing gut microbes regulate adult neurogenesis via the aryl hydrocarbon receptor</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><fpage>e2021091118</fpage><pub-id pub-id-type="doi">10.1073/pnas.2021091118</pub-id><pub-id pub-id-type="pmid">34210797</pub-id><pub-id pub-id-type="pmcid">PMC8271728</pub-id></element-citation></ref><ref id="B163-molecules-30-03628"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eckers</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heiss</surname><given-names>C.</given-names></name><name name-style="western"><surname>Haarmann-Stemmann</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brinkmann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cortese-Krott</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sansone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Esser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ale-Agha</surname><given-names>N.</given-names></name><etal/></person-group><article-title>The aryl hydrocarbon receptor promotes aging phenotypes across species</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>19618</elocation-id><pub-id pub-id-type="doi">10.1038/srep19618</pub-id><pub-id pub-id-type="pmid">26790370</pub-id><pub-id pub-id-type="pmcid">PMC4726214</pub-id></element-citation></ref><ref id="B164-molecules-30-03628"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>P.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rubio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gradin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Whitelaw</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Pettersson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hanberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poellinger</surname><given-names>L.</given-names></name></person-group><article-title>A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>9990</fpage><lpage>9995</lpage><pub-id pub-id-type="doi">10.1073/pnas.152706299</pub-id><pub-id pub-id-type="pmid">12107286</pub-id><pub-id pub-id-type="pmcid">PMC126612</pub-id></element-citation></ref><ref id="B165-molecules-30-03628"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>S&#225;ri</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Mik&#243;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kov&#225;cs</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jank&#243;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Csonka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lente</surname><given-names>G.</given-names></name><name name-style="western"><surname>Seb&#337;</surname><given-names>&#201;.</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>J.</given-names></name><name name-style="western"><surname>T&#243;th</surname><given-names>D.</given-names></name><name name-style="western"><surname>&#193;rkosy</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Indolepropionic Acid, a Metabolite of the Microbiome, Has Cytostatic Properties in Breast Cancer by Activating AHR and PXR Receptors and Inducing Oxidative Stress</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>2411</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12092411</pub-id><pub-id pub-id-type="pmid">32854297</pub-id><pub-id pub-id-type="pmcid">PMC7565149</pub-id></element-citation></ref><ref id="B166-molecules-30-03628"><label>166.</label><element-citation publication-type="gov"><article-title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects with Friedreich&#8217;s Ataxia; 2013</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT01898884" ext-link-type="uri">https://clinicaltrials.gov/study/NCT01898884</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-14">(accessed on 14 July 2025)</date-in-citation></element-citation></ref><ref id="B167-molecules-30-03628"><label>167.</label><element-citation publication-type="gov"><article-title>Indole-3-PROpionic Acid Clinical Trials&#8212;A Pilot Study (iPROACT-Pilot)</article-title><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06674018" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06674018</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-14">(accessed on 14 July 2025)</date-in-citation></element-citation></ref><ref id="B168-molecules-30-03628"><label>168.</label><element-citation publication-type="gov"><article-title>Restoration of Impaired Microbiota-Mediated Aryl Hydrocarbon Receptor Signaling in Celiac Disease by Oral Tryptophan Supplementation: An Exploratory, Pilot Trial</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05576038" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05576038</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-14">(accessed on 14 July 2025)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="molecules-30-03628-f001" orientation="portrait"><label>Figure 1</label><caption><p>Tryptophan metabolic pathways. Abbreviations: 3-HAA, 3-hydroxyanthranilic acid; 3-HAO, 3-hydroxyanthranilate 3,4-dioxygenase; 3-HK, 3-hydroxykynurenine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HT, 5-hydroxytryptamine; 5-HTP, 5-hydroxytryptophan; AA, anthranilic acid; AAAD, aromatic L-amino acid decarboxylase; AANAT, arylalkylamine N-acetyltransferase; ACMS, aminocarboxymuconate semialdehyde; acdA, acyl-CoA dehydrogenase A; ArAT, aromatic amino acid transaminase; ASMT, acetylserotonin O-methyltransferase; CNS, central nervous system; fldBC, phenyllactate dehydratase BC; fldL, phenyllactate dehydratase L; IA, indoleacrylic acid; IAA, indole-3-acetic acid; IDO, indoleamine 2,3-dioxygenase; ILDH, indolelactate dehydrogenase; ILA, indolelactic acid; IPyA, indole-3-pyruvic acid; IPA, indole-3-propionic acid; KATs, kynurenine aminotransferases; KMO, kynurenine 3-monooxygenase; KYNA, kynurenic acid; KYNU, kynureninase; L-KYN, L-kynurenine; NAD<sup>+</sup>, nicotinamide adenine dinucleotide (oxidized form); NAS, N-acetylserotonin; PIC, picolinic acid; QPRT, quinolinate phosphoribosyltransferase; QUIN, quinolinic acid; TDO, tryptophan 2,3-dioxygenase; TnaA, tryptophanase; TpH, tryptophan hydroxylase; Trp, tryptophan; TrpD, anthranilate phosphoribosyltransferase (trpD gene product). Created in BioRender. Drobek, D. (2025) <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/0c885zc">https://BioRender.com/0c885zc</uri> (accessed on 2 September 2025).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03628-g001.jpg"/></fig><fig position="float" id="molecules-30-03628-f002" orientation="portrait"><label>Figure 2</label><caption><p>IPA targets. Abbreviations: AhR, aryl hydrocarbon receptor; IPA, indole-3-propionic acid; MMP, matrix metalloproteinase; NF-&#954;B, nuclear factor kappa-light-chain-enhancer of activated B cells; PXR, pregnane X receptor; ROS, reactive oxygen species; Trp, tryptophan. Created in BioRender. Owe-larsson, M. (2025) <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://BioRender.com/7axblh2">https://BioRender.com/7axblh2</uri> (accessed on 2 September 2025).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="molecules-30-03628-g002.jpg"/></fig><table-wrap position="float" id="molecules-30-03628-t001" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03628-t001_Table 1</object-id><label>Table 1</label><caption><p>Neuroprotective effects of IPA in preclinical studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Subjects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Experimental Paradigm</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>In vitro studies</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Primary hippocampal neurons; neuroblastoma cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD model-exposure to A&#946;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#181;M IPA for 24 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA inhibited A&#946;-induced lipid peroxidation, prevented neuronal death.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-molecules-30-03628" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuroblastoma cells; mouse brain endothelial cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurodegeneration model-induced.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA-derived and 5MICA-derived hydrazone hybrids tested at up to 200 &#956;M.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA derivatives protected neurons against oxidative stress, inhibited MAO-B, and preserved BBB integrity&#8212;supporting their neuroprotective potential.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-molecules-30-03628" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enteric glial cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD model-rotenone (600 nM, 72 h).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA at 0.1 &#956;M co-administered with rotenone.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA inhibited IL13R&#945;1/JAK1/STAT6 signaling.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-molecules-30-03628" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BV2 microglial cells and SH-SY5Y neuronal cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPS-induced inflammation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#956;M IPA for 6 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA reduced release of TNF-&#945;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hippocampal HT-22 neurons</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>-induced oxidative stress.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pretreatment with or without GPR30 antagonist of G15 for 2 h, incubation with IPA (250 and 500 &#181;m) for 24 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA alleviated neurodegeneration upregulation of AMPK/SIRT1 pathway, and neuronal apoptosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-molecules-30-03628" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat brain microvascular endothelial cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BBB model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pretreatment with 2 mM IPA in DMSO for 2 h before OGD.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA reduced oxidative stress, MMP activity, and apoptosis; effect mediated via activation of PXR and inhibition of NF-&#954;B signaling.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-molecules-30-03628" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">hCMEC/D3 endothelial cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BBB model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA 1 &#181;M for 24 h + Ox-LDL 50 &#181;g/mL for 12 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA preserved BBB integrity, improved endothelial function, and exerted protective effects via FFAR3 activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-molecules-30-03628" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Astrocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Release of gliotransmitters which impact cell viability.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA 0.001&#8211;0.1 mM for 10 min; pre-treatment 24 h.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No effect on ATP and glutamate release from astrocytic cells.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-30-03628" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Astrocytes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPS-induced cytotoxicity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA (50 &#956;M) or butyrate before LPS (1 &#956;g/mL) stimulation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA decreased LPS-evoked increases in MCP-1, IL-12, IL-13, and TNF-&#945; levels.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-molecules-30-03628" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neuroblastoma cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD model-Pael-R and &#945;-synuclein overexpression in<break/>tunicamycin-induced apoptosis model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1&#8211;1 mM IPA treatment.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA suppressed protein aggregation, reduced ER stress, and protected neurons from apoptosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B42-molecules-30-03628" ref-type="bibr">42</xref>]</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>In vivo studies</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APP/PS1 transgenic mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral gavage; indole + IAA + IPA at 20 mg/kg/day for 4 weeks.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA (with other indoles) activated AhR, inhibited NF-&#954;B/NLRP3 signaling, reduced release of proinflammatory cytokines and neurodegeneration.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-molecules-30-03628" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5xFAD transgenic mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clostridium sporogenes (1 &#215; 10<sup>10</sup> CFU/day) + xylan (1% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>) orally, for 30 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved cognition and memory, reduced A&#946; pathology, enhanced synaptic structure, increased IPA levels and IPA-producing bacteria; reduced neuroinflammation, restored gut barrier integrity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B44-molecules-30-03628" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APP/PS1 male mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16-week methionine-restricted diet (0.17% <italic toggle="yes">w</italic>/<italic toggle="yes">w</italic>).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased serum IPA, improved cognition, reduced neuronal damage. IPA activated PPAR&#945; signaling and enhanced gut barrier integrity.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-molecules-30-03628" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AD model-high-fat diet induced.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABG-001 administered orally at 50 mg/kg/day for 30 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ABG-001 increased IPA, IPA targeted heat shock cognate 70 pathway (Hsc70/PKM2/HK2/LC3 and FOXO3a/SIRT1); reduced neuroinflammation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-molecules-30-03628" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6J mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes-induced cognitive impairment.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA administered orally (10 mg/kg/day for 28 days).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA improved cognitive function, and reduced neuroinflammation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-molecules-30-03628" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age-related neurodegeneration model (d-galactose).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5% CMC-Na dissolved in 0.9% NaCl in oral gavage, galactose s.c. 300 mg/kg/day for 8 weeks, 50 mg kg<sup>&#8722;1</sup> IPA.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA alleviated neurodegeneration by reducing oxidative stress, inflammation, and neuronal apoptosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-molecules-30-03628" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6J mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PD model-rotenone (30 mg/kg, i.g., 4 weeks).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA orally at 25, 50, or 100 mg/kg/day for 6 weeks.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA reduced EGC gliosis, neuroinflammation, and intestinal/brain barrier damage.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-molecules-30-03628" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCAO model of ischemic stroke.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA intragastrically administration at 400 &#956;g/20 g/day during MCAO.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA restored gut microbiota composition, enhanced intestinal barrier integrity, modulated Treg/Th17 balance, reduced neuroinflammation and infarct size, and improved neurological function.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-molecules-30-03628" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wild-type and germ-free mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MCAO model of ischemic stroke.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA (50 mg/kg/day, oral gavage) given for 14 days post-stroke.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA treatment reduced neuroinflammation, improved neurological function, and rebalanced AHR ligand pools derived from host (kynurenine pathway) and microbiota (tryptophan catabolites).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-molecules-30-03628" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aged C57BL/6 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Postoperative delirium-like behavior induced by anesthesia/surgery.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA (0.0625 mmol/kg) in 0.9% NaCl:ethanol (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> 10:1) injected 2&#215;/day at</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA modulated aberrant hippocampal neural activity and reduced delirium-like behavior in aged mice.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-molecules-30-03628" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sensorineural hearing loss induced by TCP exposure.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 mg/kg of IPA orally for 21 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA preserved hearing and cochlear structure, reduced oxidative stress, and activated immune defense via neutrophil and IFN-&#947; signaling.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-molecules-30-03628" ref-type="bibr">51</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intrauterine growth retardation model of autism spectrum disorder.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA orally administered at 20 mg/kg/day for 4 weeks starting at postnatal week 4.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA ameliorated autism-related behaviors, normalized microglial synaptic pruning, reversed NF&#954;B upregulation, and upregulated synaptic markers PSD95 and SYN.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-molecules-30-03628" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice with 16p11.2 deletion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autism spectrum disorder model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral IPA (20 mg/kg/day) or vehicle from postnatal day 42 for 2 weeks, followed by behavioral testing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16p11.2 mice exhibited altered gut microbiota and reduced IPA levels; IPA supplementation improved memory and social behavior and restored inhibitory signaling in the hippocampus.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-molecules-30-03628" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BBB function.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA 100 mg/kg/day orally for 12 weeks (in vivo); dietary Trp supplementation (0.1%/0.5%).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA preserved BBB integrity, improved endothelial function, and exerted protective effects via FFAR3 activation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-molecules-30-03628" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neonatal<break/>Sprague-Dawley rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rBMEC cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA (15 mg/kg, IP) 2&#215;/day (2 days before ligation of the common carotid artery, and a after operation and hypoxia).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA preserved BBB integrity by reducing inflammation, oxidative stress, MMP activity, and apoptosis; effect mediated via activation of PXR and inhibition of NF-&#954;B signaling.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B39-molecules-30-03628" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6J, Ifnar1<sup>&#8722;/&#8722;</sup>, IL-27ra<sup>&#8722;/&#8722;</sup>, GFAP-Cre, and AhR<sup>fl/fl</sup> mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Experimental EAE model of MS.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA administered via oral gavage at 400 &#956;g/20 g body weight/day daily from day 22 after induction of EAE.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Administration of IPA alleviated EAE symptoms in AhR-dependent way.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B54-molecules-30-03628" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neurotoxicity induced by epirubicin.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Co-administration of IPA at 20 or 40 mg/kg/day orally for 28 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA protected against epirubicin-induced neurotoxicity by modulating oxidative and inflammatory pathways.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-molecules-30-03628" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#8211;Dawley rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trp pathway.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral IPA at 200 mg/kg; subchronic feeding at 100 mg/day or 350 mg/day for 7 days.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA increased brain and plasma levels of IPA and KYNA;<break/>Subchronic feeding raised plasma IPA ~19&#8211;27&#215; and brain IPA ~2&#8211;3&#215;.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-molecules-30-03628" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Male C57BL/6 mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sciatic crush model of peripheral nerve injury.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral gavage or i.p. injection of IPA; 10 or 20&#8201;mg&#8201;kg<sup>&#8722;1</sup> per day.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA production by <italic toggle="yes">Clostridium sporogenes</italic> was required for efficient axonal regeneration; IPA delivery after sciatic injury accelerated sensory function recovery.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-molecules-30-03628" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#8211;Dawley rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Traumatic brain injury model.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Serum IPA level determination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IPA serum levels initially exhibited a downward trend; after 3 days, the trend was reversed.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-molecules-30-03628" ref-type="bibr">57</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: 5-MICA, 5-methoxy-1H-indole-3-carbonitrile; ABG-001, tetradecyl 2,3-dihydroxybenzoate; AD, Alzheimer&#8217;s disease; AhR, aryl hydrocarbon receptor; AMPK, 5&#8242;AMP-activated protein kinase; A&#946;, &#946;-amyloid; BV2, mouse microglial cell line; CFU, Colony Forming Unit; DMSO, dimethyl sulfoxide; EAE, autoimmune encephalomyelitis; EGC, enteric glial cells; FFAR3, free fatty acid receptor 3; FOXO3a, forkhead box O3; GPR30, G protein-coupled receptor 30/G protein-coupled estrogen receptor 1; GPX4, glutathione peroxidase 4; H<sub>2</sub>O<sub>2</sub>, hydrogen peroxide; CMEC/D3, immortalized human brain microvascular endothelial cell line; HK2, hexokinase 2; Hsc70, heat shock cognate 70 kDa protein; HT-22, mouse hippocampal neuronal cell line; IL-12/13, interleukin 12/13; IL13RA1, interleukin 13 receptor subunit alpha 1; IPA, indole-3-propionic acid; JAK1, Janus kinase 1; KYNA, kynurenic acid; LC3, light chain 3; LPS, lipopolysaccharide; MCAO, middle cerebral artery occlusion; MCP-1, monocyte chemoattractant protein-1; MI/R, myocardial ischemia-reperfusion; MMP, matrix metalloproteinase; MS, multiple sclerosis; NF-&#954;B, nuclear factor kappa-light-chain-enhancer of activated B cells; NLRP3, NLR family pyrin domain containing 3; Nrf2, nuclear factor E2-related factor 2; OGD, oxygen and glucose deprivation; PD, Parkinson&#8217;s disease; PKM2, pyruvate kinase muscle isozyme; PPAR&#945;, peroxisome proliferator-activated receptor &#945;; PS, presenilin 1; PSD-95, postsynaptic density protein 95; PXR, pregnane X receptor; rBMECs, rat brain microvascular endothelial cells; SH-SY5Y, human neuroblastoma cell line; SIRT1, sirtuin 1/silent information regulator 1; STAT6 signal transducer and activator of transcription 6; SYN, synuclein; TCP, 3,5,6-Trichloro-2-pyridinol; Th17, T helper 17 cells; TNF-&#945;, tumor necrosis factor-&#945;; Treg, regulatory T cells.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="molecules-30-03628-t002" orientation="portrait"><object-id pub-id-type="pii">molecules-30-03628-t002_Table 2</object-id><label>Table 2</label><caption><p>Effects of IPA on neurodegeneration in clinical studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Controls</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mild cognitive impairment patients who proceeded to AD (<italic toggle="yes">n</italic> = 19).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with stable mild cognitive impairment (<italic toggle="yes">n</italic> = 29).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An insignificant increasing trend of plasma IPA from stable mild cognitive impairment to AD.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-molecules-30-03628" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with PD (<italic toggle="yes">n</italic> = 56).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age- and sex-matched healthy participants (<italic toggle="yes">n</italic> = 43).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher IPA levels in the plasma of PD patients compared to controls (1.26 vs. 0.83 &#956;M); no correlation of IPA with cognitive and motor status scores of the patients.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-molecules-30-03628" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with stroke (<italic toggle="yes">n</italic> = 60).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age-matched controls without stroke (<italic toggle="yes">n</italic> = 64).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased serum IPA from 1 to 7 days after stroke.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-molecules-30-03628" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with acute cerebral infarction (<italic toggle="yes">n</italic> = 197).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Participants from a community-based stroke screening program (<italic toggle="yes">n</italic> = 53).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low serum IPA served as an independent predictor of acute stroke and poor prognosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B59-molecules-30-03628" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with premanifest (<italic toggle="yes">n</italic> = 52) and early symptomatic (<italic toggle="yes">n</italic> = 102) HD.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy controls (<italic toggle="yes">n</italic> = 140).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased plasma IPA levels in both groups: 138.5 ng/mL (premanifest HD) and 107.7 ng/mL (early symptomatic HD) vs. control (191.1 ng/mL).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B25-molecules-30-03628" ref-type="bibr">25</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patients with relapsing&#8211;remitting multiple sclerosis (<italic toggle="yes">n</italic> = 47).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy controls (<italic toggle="yes">n</italic> = 43).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EDSS scores were significantly correlated with the urine concentration of IPA (r = 0.5, <italic toggle="yes">p</italic> &lt; 0.001).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-molecules-30-03628" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy elderly individuals (&#8805;65 years of age) receiving probiotics (<italic toggle="yes">n</italic> = 32).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Healthy elderly individuals (&#8805;65 years of age) receiving placebo (<italic toggle="yes">n</italic> = 31).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Elevated IPA levels were positively associated with serum BDNF levels in the probiotics group (r = 0.28, <italic toggle="yes">p</italic> &lt; 0.05).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-molecules-30-03628" ref-type="bibr">33</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD, Alzheimer&#8217;s disease; BDNF, brain-derived neurotropic factor; EDSS, Expanded Disability Status Scale; HD, Huntington&#8217;s disease; IPA, indole-3-propionic acid; PD, Parkinson&#8217;s disease.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>